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Abstract 
Introduction: Frailty and sarcopenia are related concepts that can impact outcomes after 
kidney transplantation. Measures of these two entities and new/emerging metrics of 
sarcopenia remain to be validated. 
Methods: In a prospective cohort study, kidney and kidney-pancreas transplant recipients 
were assessed at the time of transplant with the Physical Frailty Phenotype, bioimpedance 
analysis, quadriceps muscle layer thickness (QMLT), and CT. The impact on length of stay 
(LOS), prediction of frailty/sarcopenia, and relative concordance of metrics were analyzed. 
Results: Low QMLT, a putative surrogate of sarcopenia/frailty, was more frequently 
associated with longer LOS (>14 days) after transplant. Additionally, QMLT was predictive 
of low muscle mass but insufficient at discriminating true sarcopenia, while CT of the 
abdominal muscles at the L3 level showed good discrimination for sarcopenia.  
Conclusions: Further exploration of QMLT and cut-offs for CT and functional metrics in the 
transplant population are required for future studies and risk stratification. 
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Summary for Lay Audience 
Kidney failure leaves patients dependent upon either dialysis or kidney transplant to stay 
alive. While waiting for transplant, patients can become frail due to age, co-morbid disease, 
or kidney failure itself.  Frailty leads to susceptibility to disease and complications from 
illness and surgery. Underpinning frailty is sarcopenia, or the loss of muscle characterized by 
both loss of muscle mass, and strength; having good strength with lower overall muscle mass 
does not make one sarcopenic.  
The relationship between frailty, sarcopenia and the outcomes of kidney transplant, were 
explored. We studied the utility of using ultrasound measurement of thigh muscles to see if 
muscle thickness could identify frailty and sarcopenia, and if it could predict how long 
someone stayed in hospital after transplant. Overall, people with thicker/more muscle had 
shorter stays in hospital than those with less muscle in the thighs, with an average of 4 days 
less in hospital (8 vs. 12 days). While significant, those with thicker thigh muscles more 
often had someone donate a kidney to them, rather than receiving a deceased donor kidney. It 
is known that living donor recipients have shorter hospital stays, so the impact of thigh 
muscle thickness is difficult to interpret.  Thigh muscle thickness was not clearly associated 
with frailty, but it did show correlation with low overall muscle mass. Despite this, thigh 
muscle thickness did not reliably predict sarcopenia, which relies on both muscle mass and 
function. 
Valid measures for identifying sarcopenia in those undergoing transplant are evolving, so we 
explored how well different measures of sarcopenia compared to CT scan data.  We 
measured the total cross sectional area of the muscles in the torso/core and compared these 
values to our other measures of muscle (using a body composition analyzer), and strength 
and walking speed as measures of muscle function. CT provided a relatively good ability to 
identify sarcopenia (both low muscle mass and strength), with analysis of a single CT 
picture.  This holds promise for refining how we identify patients with sarcopenia in both 
research and clinical practice with the aim to provide ways of treating/preventing sarcopenia 
in the future.  
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Chapter 1  
1 Renal Transplantation, Frailty, and Sarcopenia 
1.1 Brief primer on renal transplantation 
End stage renal disease (ESRD) is a chronic health state leaving patients dependent on 
one of several forms of renal replacement therapy, with initiation of dialysis as the most 
common and accessible form.  The gold standard of renal replacement is kidney 
transplantation due its impact on longevity, quality of life, and cost-savings.1-4 As 
medical care advances, the population of patients on dialysis awaiting a kidney transplant 
has overall become older, sicker, and made to wait longer for a transplant than initial 
reports on the benefits of transplant.3  Despite this, the improved outcomes of 
transplantation relative to remaining on dialysis are still seen in contemporary studies of 
transplant outcomes.3  Recent data suggest that even in the elderly transplant recipients, 
the overall risk of death may be reduced up to 61% compared to remaining on dialysis, 
and is associated with an improved life expectancy overall.5 
The number of patients awaiting a kidney transplant is high, and continues to grow.  The 
Canadian Organ Replacement Register (CORR) reported 3,106 adults in Canada were on 
the wait list for a kidney transplant in 2017 (with this number increasing year over year), 
while 38,833 were living with ESRD overall.6  The rate of kidney transplantation has 
increased over the last decade, but the number of patients remaining on the wait list 
remains stable4: 
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Figure 1. Relationship between the number of kidney transplants performed and 
the number remaining on the waitlist in Canada 
Terner, M., et al. (2016). "Increasing Rates of Kidney Failure Care in Canada Strains Demand for Kidney Donors." 
Healthc Q 19(3): 10-12. 
 
Given the relative scarcity of access to transplantable kidneys, the priority to optimize 
outcomes becomes self-evident. 
The transplant procedure classically involves an extraperitoneal dissection of the 
pelvic/lower abdominal vasculature with temporary interruption of blood flow to the 
lower limb, vascular anastomosis, and establishment of urinary drainage, most often via 
anastomosis to the native bladder or ureter.  Surgery-induced physiologic stress can be 
significant, with induction of anesthesia, extensive abdominopelvic dissection, and 
significant fluid shifts.  In a recent Canadian report, the rates of Clavien-Dindo Grade 2 
or greater complications post-transplant were found to be 60%, with 15% experiencing 
complications Grade 3b or worse.7  With the ESRD population waiting longer for 
transplant, and the average age of this population increasing, careful consideration should 
be paid to identifying factors that may predispose to poorer outcomes, with the aim of 
mitigating complications via improved patient selection, risk counselling and 
stratification, and potentially interventions to alter risk.  
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1.2 Review of the Literature 
1.2.1 Frailty 
The concept of frailty has become an established and refined clinical term, initially 
arising from the geriatrics literature.  Frailty is a complex construct, but has become 
generally understood and appreciated as a state that represents a loss of physiologic 
reserve or physiologic dysregulation.8  In general, the presence of frailty is considered to 
represent a general inflammatory state that may be associated with a reduced ability to 
withstand physiologic insults associated with disease.8-10  Fried and colleagues (2001) 
contributed significantly to the establishment of a contemporary framework for defining 
frailty. Frailty had previously been considered similar to being old, disabled, or otherwise 
lacking potential for longevity, but in recent years has been more accurately defined as a 
measurable phenotype of an underlying syndrome.11  This geriatric syndrome has been 
explored to not only identify patients at risk, but to also differentiate frailty from co-
morbidity, as the two concepts are related but not interchangeable.11,12   
 
The Frailty Phenotype, commonly referred to as the Fried score, Fried Phenotype, or 
Physical Frailty Phenotype, defines patients as frail if they possess 3 or more of the 
following attributes: shrinking (unintended weight loss of ≥ 10 pounds in the prior year), 
weakness (measured by hand grip strength compared to the weakest 20% of the 
population), poor endurance or energy (based on self-report of exhaustion), slowness 
(measured by 15 foot walk test compared to the slowest 20% of the population), low 
physical activity (a weighted score of energy expenditure per week derived from 
participant report of activity levels).11  Those possessing 2 attributes are considered pre-
frail, and those with 0-1 are non-frail.  Based on data from the Cardiovascular Health 
Study, a prospective observational study of 5,201 men and women over 65, these five 
components of the Frailty Phenotype were validated as predictors of falls, worsening 
mobility, incident hospitalization, and death.11  
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Other means of quantifying frailty exist and are used in clinical practice. Alternative 
frailty instruments provide clinical practitioners with options that come with their own 
relative strengths and weaknesses.12   The Fried score allows for distinct categorization 
(non-frail, pre-frail, frail) based on an assigned score derived from reported symptoms 
and performance on tests.8,11 A competing frailty instrument, developed in a similar 
vintage, is the Clinical Frailty Scale.13  The Clinical Frailty Scale (CFS) was derived from 
data in the Canadian Study of Health and Aging, whereby the initial quantification of 
frailty began with scoring based on an a priori list of clinical deficits (70 in total), and 
through several  iterations of assessment a 7-point scale  was created to score frailty 
based on clinical judgement of a healthcare practitioner.13   
 
Figure 2. Clinical Frailty Scale 
Rockwood, K., et al. (2005). "A global clinical measure of fitness and frailty in elderly people." 
CMAJ 173(5): 489-495. 
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A unifying definition of frailty, and the best way to quantify this concept, remains a work 
in progress.12  The relative merits of different approaches to measuring frailty should be 
considered when applying such instruments to clinical or research scenarios. Overall, the 
Fried frailty phenotype represents the most often utilized frailty score in the literature.  
 
1.2.1.1 The impact of Frailty on ESRD 
While frailty and co-morbidity are distinct concepts, there remains considerable overlap 
between the “frail” and “co-morbid” populations.  One such population of interest 
include those living with chronic kidney disease (CKD). CKD patients, and especially 
those with end-stage renal disease (ESRD), are in an extremely vulnerable health state.  
Given that frailty is often considered an inflammatory state, and ESRD is also associated 
with chronic inflammation, a shared pathophysiology becomes evident or at least 
plausible.10  In a systematic review by Chowdhury and colleagues (2017), the relationship 
between frailty and CKD was explored.10  In this review, most studies examining frailty 
in the setting of CKD have utilized the Fried phenotype, with 27 of 32 studies using it as 
their determinant of frailty. Despite the apparent consensus on its use, there were several 
variations of its use, with alternative interpretations of the components of the phenotype.  
The second most common metric of frailty was the CFS, employed by 3 of the 32 
reviewed studies.  Other instruments used included the FRAIL scale, Groningen Frailty 
Indicator, Montensanto approach, Edmonton Frail Scale, and frailty checklist.10  When 
the Fried score was used to assess frailty, the prevalence of frailty ranged from 14-73% in 
dialysis dependent populations.  The vast discrepancy between studies is attributed to 
modifications of the Fried scoring system, where patient reported scores in place of 
objective measurements are thought to over-estimate the prevalence of frailty.10 
 
The relationship between renal dysfunction and frailty has been demonstrated in large 
prospective studies.  Dalrymple et al (2013) examined the relationship between degree of 
renal dysfunction and both prevalent and incident frailty.  Drawing from the population in 
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the Cardiovascular Health Study (community dwelling adults over the age of 65, without 
evidence of Alzheimer disease, Parkinson disease, stroke), 4,150 individuals were 
stratified by renal function to define the population exposure of interest, and the outcome 
of frailty was assessed at two time points.  Renal function (eGFRcys) was quantified by 
the 2008 CKD-EPI cystatin-c equation, and frailty by the original Fried phenotype score.  
Prevalent frailty was quantified at a specific time point in the longitudinal study, and 
incident frailty derived 4 years after.  The relationship between renal function and 
prevalent frailty was strong, with decreasing eGFRcys associated with higher rates of 
frailty14: 
  
Figure 3. The prevalence of frailty stratified by level of kidney function 
Dalrymple, L. S., et al. (2013). "Kidney function and prevalent and incident frailty." Clin J Am Soc 
Nephrol 8(12): 2091-2099. 
 
Incident frailty followed a similar trend.  Logistic regression analysis estimated an 
adjusted incidence rate ratio for frailty of 3.08 in those with eGFRcys 15-44 
mL/min/1.73m2 compared to those with eGFRcys ≥ 90 mL/min/1.73m
2.  These findings 
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lend support to a shared pathophysiology between CKD and frailty, since the onset of 
frailty was not heralded by the initiation of dialysis in this population. Clearly, frailty sets 
in prior to the need for renal replacement.14 
 
The prevalence of frailty at the time of dialysis initiation has also been described.  Bao 
and colleagues (2012) reported on a population undergoing dialysis initiation in an effort 
to delineate if frailty drove dialysis initiation at higher relative eGFR levels.15  In this 
examination of data from the Comprehensive Dialysis Study, prospective assessment of 
incident maintenance dialysis was related to frailty phenotype at the time of initiation.  
Frailty was assessed using a modified version of the Fried phenotype that had been 
published previously, whereby weight loss was omitted due to non-capture of data, 
slowness and weakness defined by a score of <75 on the physical functioning scale of the 
SF-12 survey, and exhaustion criterion defined by responses to other items on this 
survey.  The overall prevalence of frailty was 73% in this population, with a prevalence 
of 63% in patients under 40 years of age. Being frail was significantly associated with a 
higher mean eGFR at initiation of dialysis (10.4 vs 8.8 mL/min/1.73m2) as well as a 
higher risk of death (HR = 1.57 at median 2.9 years of follow up).  The higher eGFR at 
initiation of dialysis may represent the misappropriation of symptoms as uremic 
complications as opposed to manifestations of frailty.15  On the other hand, uremia may 
be contributory to the clinical phenotype that defines frailty according to the Fried score. 
These authors estimate that the difference in eGFR at the time of dialysis initiation 
translates to an average of 3 additional dialysis free months in the non-frail.15 
 
1.2.1.2 The impact of Frailty on Kidney Transplant Outcomes 
The impact of kidney transplantation on outcomes in ESRD is well appreciated, with 
demonstrable improvements in quantity and quality of life.1-3  Overall, these benefits of 
kidney transplant are seen in frail populations as well9, but frailty may influence the 
outcomes of those undergoing transplantation.  It has been demonstrated in a multi-centre 
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cohort study of patients on the waitlist for kidney transplant that those deemed frail using 
the Fried phenotype experience a significantly increased risk of waitlist mortality (HR = 
2.19).16  
  
The impact of frailty on outcomes post-transplant are manifold.  In a prospective study of 
183 patients with ESRD at a single institution, Garonzik-Wang and colleagues (2012) 
demonstrated that frailty predicted the occurrence of delayed graft function (DGF) in 
kidney transplant recipients.17   These authors found the prevalence of frailty (defined 
using the Fried phenotype) to be 25% in their population of patients undergoing kidney 
transplant.  Frailty was associated with a DGF rate of 30% compared to a DGF rate of 
15% in the non-frail. After adjustment for donor and recipient confounders, the relative 
risk of DGF was calculated at 1.94. Interestingly, the effect of frailty was found to be 
independent of age.17 This reinforces the idea that frailty is related to but not entirely 
driven by age. An explanation for the relationship between frailty and DGF is thought to 
be due to systemic inflammation17, as frailty represents a manifestation of a pro-
inflammatory state and DGF may be related to pre-transplant inflammation.18  The 
influential role of frailty on rates of DGF may potentially contribute to risk stratification 
as well as refine perioperative risk counselling. 
 
Further examination of the potential influence of frailty on kidney transplant outcomes 
has taken place in the intermediate post-operative period as well.  A prospective cohort 
analysis by McAdams-DeMarco et al (2013) found that frailty predicted early re-
admission to hospital after kidney transplant.  In their cohort of 383 kidney transplant 
recipients, the authors found that frail recipients, assessed by the Fried phenotype, were 
more likely to experience early hospital readmission, defined as ≥1 hospitalizations 
within 30 days of discharge (46 vs 28%). After adjustment for several possible 
confounders including sex, age, BMI, donor factors, and immunologic risk, frailty 
conferred an adjusted risk ratio of 1.61 for the occurrence of early readmission.19 
Consistent with other reports, the impact of frailty did not differ with age.  When these 
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authors added frailty to a previously published registry-based model to predict 
readmission post-transplant, the receiver operator area under the curve was significantly 
higher with the addition of frailty to the model.19  Again, frailty represents a measurable 
factor that can help further risk stratify kidney transplant recipients as well as those who 
are pending transplant. 
 
Length of stay after transplant has also been shown to be influenced by frailty in a hybrid 
registry-augmented analysis.20 Using data (74,859 patients) from the Scientific Registry 
of Transplant Recipients, risk factors for prolonged length of stay were assessed with 
precise estimated coefficients, identifying both recipient and donor factors that predicted 
prolonged stay in hospital.  The authors then linked this registry data with their local 
cohort of 589 transplant recipients with the added variable of frailty, measured by the 
Fried score, and used the constrained coefficients of the known predictive factors to 
estimate the independent influence of frailty.  Frail kidney transplant recipients had a 
1.14-fold longer length of stay on average, and had a 1.6-fold greater likelihood of 
hospitalization beyond 2 weeks.20  This novel data analysis model provided granular 
estimation of risk from confounding factors affecting length of stay while allowing for 
the emergence of frailty as an independent risk factor for increased length of stay.  
 
The impact of frailty on kidney transplant outcomes goes further, with implications for 
mortality as well.  In a similar hybrid registry-augmented model described above, the 
same group of authors identified frailty as being an independent predictor of mortality in 
the kidney transplant recipient population.21  After adjusting for relevant confounders, 
transplant recipients deemed frail by the Fried score carried 2.17-fold increased risk of 
mortality compared to their non-frail counterparts.21  As has been seen in the general 
elderly and CKD populations, the impact of frailty on mortality persists after transplant. 
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An important consideration regarding frailty is the potentially dynamic nature of the 
phenotype.  Chu et al (2019) reviewed frailty scores in a cohort of 569 transplant 
recipients assessed both at the time of transplant evaluation and at the time of transplant.  
The authors categorized patients’ change in frailty status in one of three ways: binary 
(frail/non-frail), a 3-category state (frail/intermediate/non-frail), or raw frailty score 
change.  At a median of 1.1 years between assessment and transplant, 22% of recipients 
became more frail, 24% became less frail, and 54% remained stable in their frailty 
category.  Those who became more frail had a greater than 2-fold increased risk of 
mortality and hospital stay ≥2 weeks after transplant compared to those who remained 
stable in their frailty state.  Additionally, drivers of worsening frailty seemed to relate to 
age, history of diabetes, and cause of ESRD.22  While half of patients remained in their 
frailty category between the time of assessment and transplant, a balanced number 
worsened or improved.  This highlights the potential for frailty to change over time, and 
suggests serial evaluation may be required if frailty is to be used for risk stratification for 
transplant.  Understanding the pathophysiologic contributors to frailty may allow 
targeting of modifiable factors underlying patients’ frail states, potentially improving 
longevity and outcomes of transplantation. 
 
1.2.1.3 Biologic Mechanisms of Frailty 
The biologic basis for the clinical phenotype of frailty is complex, but is becoming better 
elucidated over time. Exterkate and colleagues (2016) reviewed the impact of frailty on 
kidney transplant outcomes, highlighting the evidence for underlying pathophysiologic 
mechanisms.  In their review, the authors note several unifying mechanisms for frailty 
relating to cellular senescence and a resultant impaired homeostasis, with eventual 
dysregulation of both energy metabolic systems and the neuromuscular system.5   
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Figure 4. The relationship of possible risk factors and clinical states contribuitng to 
frailty in the ESRD population 
Exterkate, L., et al. (2016). "Frailty and Transplantation." Transplantation 100(4): 727-733. 
 
Their review describes the immunologic sequelae of frailty, underpinned by evidence of 
systemic inflammation in the form of heightened levels of Interleukin 6 (IL-6), Interferon 
gamma (IFN-gamma), and C-reactive protein (CRP).  These authors also describe 
specific immune changes that they consider a hallmark of frailty, including elevated 
amounts of CD8+ T cells and a lower CD4+:CD8+ ratio, as well as several other 
alterations in T cell surface markers.5 Although the clinical significance of these 
variations in cell surface markers in frail patients is not fully understood now, it stands to 
reason there may be a potential interplay between frailty and immunologic response to 
transplant. 
12 
 
1.2.2 Sarcopenia 
1.2.2.1 Definitions and Pathophysiology of Sarcopenia 
Skeletal muscle comprises a significant proportion of an individual’s lean body mass, and 
accounts for approximately half of the body’s total protein energy stores23; the loss of 
lean muscle mass has been termed sarcopenia. As protein is an essential component to the 
normal function of all organs and organ systems, protein reserves are sometimes called 
upon to supplement protein and amino acids in states of decreased protein intake or 
inflammatory disease states.23  Aging in and of itself represents a significant contributor 
to sarcopenic changes. “Sarcopenia of aging” is the term granted to age related muscle 
loss, and begins early in life, with an estimated 0.1-0.5% muscle mass decline per year 
beginning at age 30, with significant acceleration after age 65.24  The prevalence of 
sarcopenia has been estimated at between 5-50% in the elderly general population.25  No 
standard or widely accepted definition of sarcopenia existed for several years, but the 
European Working Group on Sarcopenia in Older People (EWGSOP) in 2010 created a 
practical clinical definition as follows: “a syndrome characterized by progressive and 
generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes 
such as physical disability, poor quality of life, and death”.24,26  To this end, this group 
proposed a conceptual staging tool for the presence of sarcopenia including the following 
criteria: 1) Low muscle mass, 2) Low muscle strength, and 3) Low physical 
performance.26  The presence of criteria 1 alone, as measured by some means that 
accurately estimates muscle mass with comparators to population norms, indicated 
‘presarcopenia’.  ‘Sarcopenia’ was therefore deemed present when criterion 1 was found 
in conjunction either criteria 2 or 3, and the presence of all three indicating ‘Severe 
sarcopenia’.26 Since the proposal of this framework, several other international groups 
focusing on sarcopenia have provided operational definitions for sarcopenia.  There is 
significant agreement and overlap of these groups’ definitions of sarcopenia.27 
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Figure 5. Comparisons of different sarcopenia definitions in the literature 
Morley, J. E., et al. (2014). "Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, 
and epidemiology-update 2014." J Cachexia Sarcopenia Muscle 5(4): 253-259. 
 
The underlying mechanisms leading to sarcopenia have been described by the EWGSOP 
and is summarized in the flow diagram below.26 Sarcopenia represents a manifestation of 
multiple contributors ranging from lifestyle factors, aging, and sequelae of certain disease 
states. Furthermore, the EWGSOP suggests sarcopenia can be categorized by etiology, 
differentiating primary causes (age-related sarcopenia) and secondary causes (sarcopenia 
of inactivity, disease-associated sarcopenia, nutrition-related sarcopenia).26 
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Figure 6. Demonstration of multiple underlying etiologies contributing to sarcopenia 
Cruz-Jentoft, A. J., et al. (2010). "Sarcopenia: European consensus on definition and diagnosis: 
Report of the European Working Group on Sarcopenia in Older People." Age Ageing 39(4): 412-423 
 
Further evidence since the initial EWGSOP consensus on sarcopenia has led to an 
updated framework for the diagnosis of sarcopenia.  The EWGSOP2 met in 2018 to 
update the definition of sarcopenia to be based on the incipient criteria of low muscle 
strength, with confirmation of the diagnosis heralded by the presence of either low 
muscle quantity, and/or low physical performance.28  Muscle strength may be assessed by 
grip strength or chair stand test. Muscle quantity can be measured using dual energy X-
ray absorptiometry (DEXA), whole body or appendicular skeletal muscle mass predicted 
by bioimpedance analysis, lumbar muscle cross-sectional area by CT or MRI. Physical 
performance is assessed using gait speed, Short physical performance battery, Timed-up-
and-go test, or 400-meter walk test.28 
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In the CKD population specifically, sarcopenic mechanisms have been explored to better 
understand the pathophysiology of this phenomenon.  The metabolic acidosis inherent to 
CKD disease states leads to activation of the ubiquitin-proteasome degradation pathways, 
while elevated angiotensin II levels can activate the caspase-3 pathways and causes a 
reduction in skeletal Insulin-like Growth Factor 1 (IGF-1): these pathways all contribute 
to muscle protein wasting and apoptosis of skeletal muscle.29,30  Vitamin D is thought to 
contribute to skeletal muscle maintenance, and the relative deficiency associated with 
CKD is considered part of the mechanism for sarcopenia in this population.30 In fact, 
supplementation with vitamin D in patients on hemodialysis has been demonstrated to 
lead to increased thigh muscle cross-sectional area on MRI compared to controls.31  
Additionally, the hypogonadal state of CKD further diminishes skeletal muscle mass 
through the loss of testosterone’s anabolic influence.  Testosterone enhances/preserves 
muscle mass via stimulation of muscle protein synthesis, myoblast differentiation, 
suppression of myostatin, induction of IGF-1 messenger RNA (mRNA), and supports the 
regenerative muscle stem cells (satellite cells).32 In a randomized trial of dialysis patients, 
testosterone supplementation with or without exercise significantly increased quadriceps 
muscle cross-sectional area after 12 weeks, whereas control groups did not show any 
change.33  
 
While multifactorial in etiology, chronic systemic inflammation is thought to be a 
significant contributory factor to the development of sarcopenia, and often stems from 
chronic illness states, such as CKD.23,24,34In a cross-sectional study of patients on 
hemodialysis for at least 1 year, measurement of muscle mass via CT scanning was 
undertaken and the values were correlated with serum levels of IL-6 and CRP.  Muscle 
mass, as determined by thigh musculature cross-sectional area, was found to be 
significantly associated with both inflammatory markers after controlling for dry weight 
and creatinine kinetics.34  IL-6 has been reported as a modulator of acute-phase reactant 
plasma proteins in vivo and has been implicated in cancer associated cachexia and muscle 
breakdown; furthermore, in animal models of IL-6 transgenic mice, antibodies targeting 
the IL-6 receptor lead to attenuation of proteolysis and muscle atrophy.34   
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In addition, chronic low grade systemic inflammation has been suggested to predispose to 
sarcopenia via activation of the ubiquitin-protease pathways, diminished anabolic effects 
of hormones such as IGF-1, and subsequent ‘anabolic resistance’: a state of relative 
resistance of muscle anabolism with a given macronutrient intake.24,29  The heightened 
levels of oxidative stress associated with aging can induce immune system activation 
thereby increasing levels of inflammatory cytokines and positively feedback on the 
deleterious process of reactive oxygen species (ROS) creation in muscle, leading to 
increased proteolysis, degeneration of neuromuscular junctions, and diminished degrees 
of excitation-contraction coupling.24 The sum of these changes leads to loss of muscle 
mass and impaired muscle function, both considered defining features of sarcopenia. 
 
Oxidative stress is pervasive in states of advanced age, as well as several chronic diseases 
that often contribute to CKD, in addition to CKD itself.  The relative imbalance between 
ROS and endogenous/exogenous antioxidants leads to a predisposition towards cellular 
damage resulting in senescent cells.35  Aging cells are associated with the acquisition of a 
senescence-associated secretory phenotype that involves the constitutive secretion of 
chemokines, growth factors, and degradative enzymes.35 Diabetes mellitus can induce a 
relative imbalance of ROS via persistent intracellular hyperglycemic conditions, and 
chronic renal dysfunction can worsen ROS load via several mechanisms including 
reduced levels of nitric oxide and persistent activation of polymorphonucleocytes.35  
Even in the absence of advanced age, CKD and related conditions (i.e. diabetes) may 
induce a sarcopenic state through numerous mechanisms. 
 
Evidence for the influence of exogenous inflammation contributing to sarcopenia exists 
as well.  Hemodialysis, known to contribute to systemic inflammation through 
blood/filtration system interactions, may also contribute to the induction of sarcopenia.  
Takamoto and colleagues (2018) showed that in a cohort of patients undergoing renal 
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transplant, the time spent on dialysis was significantly associated with sarcopenia.  The 
degree of sarcopenia was worse when time on dialysis was greater than the median time 
of the cohort as compared to those with less than the median time on dialysis.36 The 
mean±SD age of this cohort was 43±16 years, suggesting the drivers of differences in 
sarcopenia for this population were likely related to CKD and dialysis itself without a 
significant influence of age. 
 
The complex nature of sarcopenia was further highlighted in a study of CKD patients 
where sarcopenia, nutritional analysis, and inflammatory markers were assessed.  When 
compared to non-sarcopenic patients, those who had evidence of sarcopenia did not have 
significantly different inflammatory marker profiles, nor did nutritional profiles 
significantly differ.29  In this cohort, the mean age of sarcopenic and non-sarcopenic 
patients was 79 and 80 years (respectively), suggesting that the influence of age related 
sarcopenia and systemic inflammation may affect individuals differently depending on 
inherent susceptibility. 
 
Because the Fried phenotype of frailty focuses on physical frailty, which stems from 
muscle function, the physiologic processes behind oxidative stress and subsequent 
sarcopenia have significant overlap with frailty pathophysiology.35  Much like frailty’s 
predictive value stems from the ability to quantify and qualify its severity, measurements 
of sarcopenia require reproducible and objective measures to operationalize its use in 
patient assessment.  The prevalence of frailty is higher in sarcopenic compared to non-
sarcopenic patients, even when age, nutritional status, and systemic inflammatory 
markers were similar.29  While they are not interchangeable phenomena, frailty and 
sarcopenia can stem from common pathophysiologic processes, conceptually represented 
in the flow diagram below. 
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Figure 7. Flow diagram illustrating the possible interplay between aging, sarcopenia 
and frailty 
Liguori, I., et al. (2018). "Oxidative stress, aging, and diseases." Clin Interv Aging 13: 757-772. 
1.2.2.2 Measuring Sarcopenia 
Functional testing, as the incipient component of sarcopenia assessment, may be done 
using hand grip strength dynamometry as well as gait speed, among other validated 
clinical tests.23 Muscle mass, a component of sarcopenia, may be quantified by one or 
more other methods.  Structural assessment can be obtained via imaging modalities, 
including cross-sectional imaging using computed tomography (CT) or magnetic 
resonance imaging (MRI), which allows measurement of specific muscle 
groups/compartments, as well as dual energy x-ray absorptiometry (DEXA). Cross-
sectional imaging has typically been considered the gold standard for assessing muscle 
mass, but the cost, availability, and potential safety issues with this type of imaging may 
limit its utility for quantifying sarcopenia.37  An alternative, lower cost assessment 
modality includes bioimpedance analysis (BIA).  In a study of kidney transplant 
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recipients, BIA estimations of skeletal muscle mass strongly correlated with psoas muscle 
volume derived from CT measurements (r=0.761), and was highly correlative with 
DEXA scanning (r=0.90).37  
 
BIA is a method of body composition assessment utilizing bioimpedance, defined as the 
vector sum of resistance (a measure inversely related to body water content) and 
reactance of body tissue (a measure of tissue capacitance that varies depending on cell 
membrane integrity, function, and composition) derived from transmitting low-amplitude 
imperceptible current passed from the wrist to the ankle.38-40 Information derived from 
BIA has been shown to be a reliable metric of body composition in the dialysis 
population, predictive of clinical frailty, and may be prognostic for survival in 
hemodialysis patients.41,42  Data obtained from BIA can provide an estimation of overall 
health status utilizing the calculation of the bioimpedance phase angle (PhA). PhA is 
thought to represent the relative health of human tissue at a cellular level, with decreased 
reactance being reflective of intact, healthy cell membranes.37  The PhA is derived from 
calculating the arc-tangent of the reactance divided by the resistance, multiplied by 
180°/π.39  A significant correlation between PhA and survival has been observed in the 
AIDS, lung cancer and critically ill populations.39  Furthermore, PhA has been suggested 
to correlate with survival in those on hemodialysis as well.43 A visual explanation of the 
relationship between reactance, resistance and phase angle is shown below.44 
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Figure 8. Graph visualizing the relationship between bioimpedance values of 
resistance, reactance, and phase angle 
Davies, S. J. and A. Davenport (2014). "The role of bioimpedance and biomarkers in helping to aid clinical 
decision-making of volume assessments in dialysis patients." Kidney Int 86(3): 489-496. 
 
Support for using BIA-derived measures of muscle mass in kidney transplant recipients 
comes from reports validating this metric.  In a cross-sectional study by Ozkayar and 
colleagues (2014) of 166 kidney transplant recipients, sarcopenia prevalence was 
assessed using hand grip strength and fat free mass determined by BIA.  Overall, 
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sarcopenia was evident in 20% of the transplant recipient population, with a mean age of 
44 in the sarcopenic group and 36 in the non-sarcopenic group.25  BIA measurement has 
also been used as a tool to derive absolute values of skeletal muscle mass.  Through 
multiple regression analysis of BIA parameters and patient demographics, Janssen and 
colleagues (2000) derived an equation to predict whole body skeletal muscle mass as 
follows:  
 
Skeletal muscle mass (kg) = [(Height2/R x 0.401) + (gender x 3.825) + (age x -0.071)] + 5.102 
 
where height is measured in centimeters, the gender value is 1 for male and 0 for female, 
and R is the measured resistance from BIA.45  This formula was created and validated in 
a population made of up of Canadian and American volunteers, initially in patients of 
Caucasian ethnicity and subsequently cross-validated in Hispanic, African-American, and 
Asian subjects, and showed high correlation with a reference measurement of total 
skeletal muscle mass derived from whole body MRI: 
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Figure 9. Graph demonstrating the correlation between bioimpedance-derived 
muscle mass and whole body MRI-derived muscle mass 
Janssen, I., et al. (2000). "Estimation of skeletal muscle mass by bioelectrical impedance analysis." J Appl Physiol 
(1985) 89(2): 465-471. 
 
Healthy volunteers aged 18-86 years old with BMIs ranging from 16-48 kg/m2 comprised 
the reference population for this equation.45  This estimating equation has been applied in 
other settings to estimate skeletal muscle mass, and has been used in a large population 
study. The NHANES III study captured BIA measurements in participants, and this data 
has been used to show that BIA-derived skeletal muscle mass, expressed as a skeletal 
muscle index (SMI = [muscle mass in kg/total body weight in kg] x 100%), can be used 
to quantify sarcopenia in the general population and correlates with degree of functional 
impairment.46 In this study by Janssen et al (2002), NHANES III participants aged 18-39 
comprised the referent population, and those in the older age groups (39+) were stratified 
by SMI, and those between 1 and 2 standard deviations below the referent population 
were deemed moderately sarcopenic, while those greater than 2 standard deviations 
below were severely sarcopenic.  The results from this report provide population 
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normative data for a North American population.46 An alternatively derived SMI, 
normalizing muscle mass to height squared (kg/m2), has also been reported in older 
populations and used to derive cut-off points that increase risk of physical disability.47 
Unfortunately, these reports do not include data on patients with CKD or ESRD/dialysis, 
and thus these estimating equations have not been validated in the renal failure 
population.48  However, population normative data of BIA parameters (tissue resistance, 
etc.) in the hemodialysis population has been published, therefore derivation of 
population norms of skeletal muscle mass/SMI could be calculated and explored as a 
reference for assessment of the dialysis-dependent population.38   
 
1.2.2.2.1 Quadriceps Muscle Layer Thickness as a Possible    
Measure of Sarcopenia 
The relative access to body composition metrics, such as DEXA or BIA, may be limited 
in some clinical settings.  Alternative point of care assessments for muscle 
mass/sarcopenia may be of use to clinicians in patient populations where sarcopenia is 
prognostic or impact clinical decision making.  While whole body assessment of skeletal 
muscle mass may represent the only true quantification of this measurement, surrogate 
measurements of regional muscle groups can be representative of whole body muscle 
mass.  In a study of whole body muscle mass with MRI, variations in the relative 
distribution of muscle were observed and quantified, with pertinent findings displayed 
below.49 
 
 
24 
 
 
Figure 10. Graph showing the relative distribution of MRI-derived muscle mass 
throughout the body 
Lee, S. J., et al. (2004). "Relation between whole-body and regional measures of human skeletal muscle." 
Am J Clin Nutr 80(5): 1215-1221. 
 
Overall, the cross-sectional area of the thigh musculature represented the highest 
correlation with whole-body muscle mass with R2=0.77 and 0.79 for males and females, 
respectively.49 Assessment of thigh musculature represents an accessible means for 
estimation of whole body skeletal muscle mass. 
 
With the relative availability of bedside/point-of-care ultrasound in most clinical settings, 
application of this technology as an assessment tool for muscle mass has been proposed 
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in both healthy and ill populations.50-53  Bedside ultrasound measurement of muscle mass 
has largely focused on the lower extremity, specifically the anterior thigh compartment. 
 
Anterior thigh muscle can be assessed using point-of-care ultrasound by measuring 
thickness or cross-sectional area of one or more individual muscles.  In healthy older 
aged females, anterior thigh muscle thickness was higher in those who participated in 
recreational golfing as compared to sedentary controls.53  Additionally, the muscle 
thickness of the anterior thigh compartment of healthy young male volunteers 
significantly increased after 12 weeks of lower body resistance training, and the increases 
in muscle thickness were found to correlate with changes in anatomic cross-sectional area 
as well as MRI-derived volume of the vastus lateralis muscle.52  These small reports 
suggest that ultrasound measurement of thigh musculature may be able to capture 
meaningful variation in muscle mass within and between subjects, creating a rationale for 
its use as a potential index of sarcopenia and/or frailty. 
 
Assessment of the quadriceps muscle layer thickness (QMLT) has demonstrated 
predictive value in the general elderly hospitalized population in terms of re-admission, 
death, and functional decline.51  In a prospective cohort study of 100 patients aged 65 or 
greater admitted to hospital for various medical conditions, Guerreiro and colleagues 
(2017) demonstrated that QMLT was associated with the co-primary endpoint of re-
hospitalization or death at 3 months post discharge (RR = 1.24).  This relationship was 
also observed in a bedridden subgroup of the cohort (RR = 1.34).  QMLT also correlated 
with functional testing as well, including gait speed, timed-up-and-go test and handgrip 
strength.51   
 
QMLT measurements have also demonstrated concordance with other measurements of 
skeletal muscle mass. Berger and colleagues (2015) showed that in healthy community 
dwelling individuals, QMLT values correlated with lower limb fat free mass (r = 0.74), as 
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well as total fat free mass derived from DEXA analysis (r = 0.71).50 Paris et al (2017) 
reported on a prospective multicentre study validating bedside derived QMLT values in 
critically ill populations.  This group found that QMLT values moderately correlated with 
absolute abdominal muscle cross-sectional area (at the L3 level) derived from CT-
scanning, with an r = 0.45.54  The strength of this relationship was largely driven by the 
younger male cohort in their population.  However, on multivariate regression analysis 
QMLT alone demonstrated a concordance index of 0.67 in predicting low muscle mass 
on CT, and this value improved to 0.77 when considered along with other covariates, 
including age, BMI, gender, type of ICU admission, and co-morbidity index.54  QMLT 
may fall short of predicting absolute muscle mass in isolation, but could represent a tool 
to help stratify patients by category of total CT-derived muscle mass.   
 
The potential application of QMLT measurement to the renal failure population requires 
consideration of population specific variables, such as the impact of fluid shifts on 
muscle thickness measurements.  Sabatino and colleagues (2017) assessed the reliability 
of QMLT measurement using bedside ultrasound in the critically ill population with 
severe acute kidney injury requiring dialysis. In their cross-sectional observational study, 
when QMLT measurements were compared pre- and post-dialysis, values did not 
significantly differ.  This was regardless of whether conventional 4-hour dialysis or 
sustained low-efficiency dialysis (6-12 hours) was used, nor did degree of weight change 
after dialysis impact QMLT measurements.55  While this population represents acute 
dialysis as opposed to a chronically dialysis-dependent population, fluid shifts were 
significant (range of -0.5 to -3.0kg of fluid removed across dialysis sessions)55, these 
results provide reassurance that a patient’s fluid status likely does not acutely influence 
QMLT measurements. 
 
Given that bedside ultrasound of the QMLT depends upon a human operator to generate 
and interpret the images, the validity of this measurement requires documentation prior to 
its implementation. Reassuringly, the intraobserver variability and interobserver 
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variability both showed excellent agreement in a cohort study by Guerreiro et al (2017)51, 
as well as other studies of similar design.56  Formal study to validate this method of 
muscle assessment in critically ill populations further supports its validity.  Hadda et al 
(2017) sought to quantify the intra- and interobserver reliability of the QMLT assessed by 
ultrasound in the pneumosepsis population.57 Measurements were obtained from the right 
thigh in the supine position with knee extended at the level of the midpoint between the 
greater trochanter and lateral joint line of the knee in the sagittal plane, with minimal 
pressure applied to the anterior thigh compartment. QMLT measures involved the muscle 
tissue just deep to the fascia of the rectus femoris muscle down to the level of just 
superficial to the periosteum of the femur (includes the vastus intermedius muscle).  Two 
observers independently completed measurements of all participants. The intra-class 
correlation (ICC) of the intraobserver variability was excellent with values of 0.925 for 
one examiner and 0.835 for the second; these ICC values suggest almost perfect 
agreement. Interobserver variability produced an ICC of 0.992, and the mean difference 
between measurements was -0.082 cm, well within the limits of agreement on Bland-
Altman analysis.57  The reliability of US derived QMLT in the critically ill population 
has been replicated by other groups. Pardo and colleagues (2018) evaluated QMLT in a 
population of patients admitted to a surgical critical care unit, obtaining measurements 
from the two-thirds distance point between the ASIS and upper patella, as well as the 
mid-point between these landmarks, and quantified changes in QMLT over time in the 
ICU, as well as intra- and interobserver variability.  The ICC of intraobserver variability 
was 0.74 while the ICC of interobserver variability was 0.76, representing moderate 
agreement.58 In contradistinction to the report by Hadda et al (2017), these authors 
performed QMLT measurement with maximal compression of the anterior thigh 
compartment to compress the muscle to account for potential underestimation of muscle 
thickness due to tissue edema. The degree of compression was targeted to be maximal 
pressure without inflicting pain.  The degree to which subcutaneous tissue may be 
compressible likely varies between ages and genders54 which may have led to variability 
in compressive force applied within and between assessors.  As well, pain infliction may 
be subjective and vary depending on patients’ state of consciousness. Thus, the lower 
ICC values could stem from this alternative approach to QMLT measurement.  On 
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balance, Paris and colleagues (2016) in a multicentre prospective study of critically ill 
patients assessed QMLT with the maximal compression method, and returned higher ICC 
values, with intrarater reliability ICC = 0.98 and interrelater reliability ICC = 0.94.54  
Other reports have demonstrated excellent intra- and interobserver agreement with a 
minimal compression technique.50,55,59 With ICC values of reliability ranging from 0.74 
to 0.99 among both minimal and maximal thigh compression methods, it appears bedside 
assessment of QMLT with either technique using ultrasound is likely reliable and 
reproducible. 
 
Further confidence in the QMLT measurement by bedside ultrasound was presented by 
Tillquist and colleagues (2014). In their prospective, multicentre international 
observational study of ICU patients, intra- and interobserver variability between 
physicians with significant point of care ultrasound experience and trainees that consisted 
of dieticians, nurses, physiotherapists, coordinators, and technicians were compared; 
most trainees had no ultrasound experience.  Instruction to trainees was provided in the 
form of a manual, instructional video, and hands-on teaching.  Within operator 
measurements produced an ICC of 0.98 across 12 study locations, and across 78 pairs of 
trainer-trainee comparisons the ICC was 0.95, with the mean difference in measurements 
not significantly different.59  Bedside US derived QMLT measurements across novice 
and expert examiners create reproducible results, and appears to have validity in the 
critically ill and dialysis dependent populations. 
 
The application of QMLT to the chronic hemodialysis dependent population (ESRD-HD) 
has been reported and supports its use as a potential metric of sarcopenia.  Sabatino and 
colleagues (2019) in a cross-sectional prospective observational study evaluated QMLT 
measurements of HD patients in comparison to healthy and age-matched hospitalized 
controls.  These authors found that QMLT values were significantly lower in the ESRD-
HD population.60  Of note, their QMLT assessment involved minimal pressure 
application of the ultrasound probe perpendicular to the anterior thigh.  Importantly, they 
29 
 
also found measurements performed pre- and post-dialysis were not significantly 
different regardless of degree of fluid shift, consistent with another report on QMLT in 
the setting of AKI.55  QMLT values were moderately correlated with several metrics of 
protein energy wasting (a contributor to sarcopenia), including BMI (r = 0.36) and serum 
albumin (r = 0.27).  This report found a stronger correlation between QMLT and the 
Malnutrition Inflammation Score (MIS), a validated tool to evaluate nutrition and risk of 
mortality in the renal failure population, where a score of 6 represents the population 
mean (r = -0.47).60,61  Patients with MIS scores of ≥ 6 had significantly lower QMLT 
values compared to those having a score of < 6.60  No reference standard of skeletal 
muscle mass was available for correlating QMLT (i.e. DEXA scans, CT scans), however 
there was a clear and consistent relationship between QMLT values and a validated 
measure of protein energy wasting, which may be considered as a surrogate for a 
sarcopenic state, and possibly frailty, in the ESRD-HD population.  QMLT therefore 
could represent as a practical tool for bedside estimation of skeletal muscle mass and 
sarcopenia/frailty, both quantitatively and qualitatively. 
 
1.3 Thesis Objectives 
This thesis addresses 3 main objectives by way of an integrated-article format. The 
overarching theme is the influence of frailty and sarcopenia on kidney transplant 
outcomes. The interrelated nature of sarcopenia and frailty, as well as the impact both 
may have on transplant outcomes, makes studying a convenient and clinically accessible 
surrogate measure attractive. The initial focus of this project was to assess the QMLT, a 
relatively novel tool, as it relates to frailty and sarcopenia. It was thought that the QMLT 
could represent a single-step, convenient method for case-detection of frailty/sarcopenia 
that could improve access to this form of testing in the clinical setting. 
 
First, the QMLT was used as a potential surrogate of frailty/sarcopenia and its impact on 
clinical outcomes.  The relationship between QMLT and length of stay in hospital after 
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renal transplant was assessed. The QMLT values delineated two cohorts for comparison 
of length of stay and other related outcomes.  
 
As a follow up, the ability of the QMLT to specifically predict sarcopenia was assessed 
by defining sarcopenic patients using EWGSOP2 criteria and comparing their attributes 
to their non-sarcopenic counterparts. This comparison allowed for assessment of the 
QMLT as a surrogate for identifying sarcopenic patients.  
 
Finally, the agreement and concordance between several different metrics of sarcopenia 
were examined, including bioimpedance derived-muscle mass, clinical metrics of muscle 
function, CT measures of muscle mass, as well as QMLT.  It was thought these 
observations will contribute to better appreciating the role each of these modalities might 
play in assessing sarcopenia in renal transplant recipients. 
 
The current literature is essentially devoid of reports examining those receiving a kidney 
in concert with a pancreas (simultaneous pancreas-kidney transplant) in the setting of 
ESRD secondary to type 1 diabetes. There has been suggestion that type 1 diabetes may 
accelerate loss of muscle mass, and a single report has documented a possibly higher rate 
of complications in sarcopenic patients undergoing pancreas transplant either with or 
without a concurrent kidney transpant.63 We therefore opted to include this population of 
transplant recipients in this project to add to this nascent area of the literature. 
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Chapter 2  
2 The Impact of Quadriceps Muscle Layer Thickness on 
Length of Stay in Those Awaiting Renal Transplant 
2.1 Introduction 
Frailty has emerged as a relevant prognostic tool in the kidney transplant population.1  As 
a construct derived from the geriatrics literature, frailty has come to be recognized as an 
accumulation of deficits leading to a reduced ability to withstand physiologic stress, in 
both the general population and those undergoing kidney transplant.2,3  Those who are 
frail have been found to have longer length of stay (LOS) in hospital after transplant.3 
Frailty has been most commonly assessed in this population using the Physical Frailty 
Phenotype, and the scoring reflects measures of muscle function, mass, and activity.2 
 
The quadriceps muscle layer thickness (QMLT) represents an emerging form of bedside 
assessment of muscle mass of the lower thigh, with validation in the critically ill, 
community dwelling elderly, and healthy populations.4-7 The QMLT has the potential to 
serve as a relatively inexpensive screening tool for identifying patients who may be frail. 
 
At present, the QMLT has not been studied in patients undergoing kidney transplant.  The 
relatively low cost and wide availability of point of care ultrasound makes this modality 
an attractive tool to explore to identify patients at risk or poor outcomes.  LOS is a metric 
of patient outcomes that is associated with reduced global healthcare costs, and is an 
objective marker of how quickly patients recover after surgery. 
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2.2 Purpose and Hypothesis 
The purpose of this study was to assess whether QMLT values obtained at the time of 
transplant in those with end stage renal disease are predictive of the total length of stay in 
hospital following transplant. 
 
It was hypothesized that those patients pending a renal transplant with lower measures of 
QMLT would have longer lengths of stay following transplant, as well as higher rates of 
infection and rejection in the early post-transplant period. 
 
2.3 Methods 
This is a prospective observational cohort study performed at London Health Sciences 
Centre University Hospital in Ontario, Canada.  Patient recruitment occurred from March 
1, 2019 until Jan 1, 2020, where all patients presenting for a kidney or combined kidney-
pancreas transplant were invited to participate. Patients were excluded if they were under 
18 years of age, receiving a concurrent liver or heart transplant, or refused to participate. 
Upon recruitment, patients provided written informed consent to participate, at which 
point data collection occurred which included, age, gender, height, weight, BMI, type of 
donor (donation after brain death [DBD], donation after circulatory death [DCD], living 
donor [LD]), panel reactive antibody (PRA%), Physical Frailty Phenotype scores, and 
quadriceps muscle layer thickness (QMLT).  
 
The Physical Frailty Phenotype was assessed using the criteria set out by Fried et al 
(2001).  Components of the Frailty Phenotype included patient reported unintentional 
weight loss of >10% over the last year, self-reported exhaustion, weekly physical 
activity, hand grip strength assessed by a Jamar dynamometer, and time to walk 15 feet at 
one’s usual pace. Gender and BMI stratified cut-offs used in clinical practice were 
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utilized for assessing the presence or absence of each frailty component. A composite 
score of >2 indicated the presence of frailty. (Appendix 1) 
 
QMLT is a measurement of the anterior thigh compartment musculature comprising the 
rectus femoris muscle and the vastus intermedius muscle.  Point of care ultrasound (BK 
technology) was used to quantify this value. With the patient in the supine position and 
feet pointed forward, a tape measure was used to measure the distance from the anterior 
superior iliac spine to the superior border of the patella, and the halfway point was 
marked with indelible ink on the anterior aspect of the thigh in the midline of the lower 
limb.  A curvilinear probe set to 6Hz and with ample ultrasound jelly assessed this point 
of the thigh musculature. The depth was adjusted so the femur and superficial adipose 
were visible at the bottom and top of the ultrasound image, respectively.  Light pressure 
was applied to observe tissue dispersion to confirm the discrimination of the visible 
layers as muscle versus adipose. Pressure was released to the point of minimal pressure 
from the probe, allowing contact with the probe to the skin with no external compression 
applied. The image was then frozen, and electronic calipers measured the vertical 
distance from the inner layer of the rectus femoris muscle fascia to the level of the femur 
periosteum to obtain the QMLT.  This measurement was repeated for a total of three 
measurements and then repeated on the contralateral thigh.  The mean value of the six 
measurements obtained comprised the patient’s QMLT value. An example of the QMLT 
being measured is depicted in Figure 11. 
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Figure 11. Representative ultrasound image capturing the quadriceps muscle layer 
thickness and electronic calipers 
 
 
Patients were then followed prospectively for outcome assessment. The primary outcome 
of interest was the length of stay in hospital following transplant, assessed both as a 
continuous variable and as a nominal variable of greater than/equal to  or less than 14 
days.  Secondary outcomes of interest included the occurrence of infectious complication, 
rejection, and renal function at 1 month post-transplant measured using serum creatinine 
level; infection and rejection assessment was limited to the first month after transplant. 
Infection was deemed present if the following criteria were met: culture evidence of 
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microbial infection with clinical symptoms and/or treatment with antimicrobials, OR 
radiographic evidence of infection with clinical symptoms and/or treatment with 
antimicrobials.  An infection was not considered present if a patient was treated with a 
course of antibiotics for prophylaxis or for pre-emptive treatment of a possible donor-
derived pathogen. Rejection was documented if there was a biopsy post-transplant 
documenting graft rejection in the presence of graft dysfunction and treatment provided 
directed at rejection. Graft function was categorized as delayed if dialysis was required 
within 7 days of transplant, and was otherwise deemed immediate. 
 
Statistical analysis was carried out using SPSS v 26.0. Demographic data was 
summarized using descriptive statistics.  QMLT values were organized by percentile. A 
cut-off of the 20th percentile was used to divide patients into two categories of QMLT 
(low and higher).  Kolmogorov-Smirnov testing assessed for assumptions of normality 
and the continuous outcomes compared using a two-sided t-test or Mann-Whitney U test 
where appropriate. Chi square analysis and Fisher exact testing for nominal variables 
were performed. Multivariable regression assessed the predictive impact of QMLT on 
LOS while controlling for relevant variables.  Alpha was set at 0.05 and all analyses were 
two-tailed.  An a priori sample size of 74 was chosen to allow for assessing the 
difference in LOS using unpaired t-test using G*Power 3.1 software, with an effect size 
of 0.67 based on local data on LOS (mean LOS = 9.0 days, S.D. = 4.5, a 3 day difference 
in LOS being deemed clinically significant).  For the purposes of multivariable regression 
to be performed on 5 variables of interest, using the guide of 15 patients per variable of 
interest, a sample size of at least 75 was sought. We therefore aimed to accrue up to 88 
patients to allow for a 10-20% rate of attrition.  Patients lost to follow up due to early 
structural graft loss or death were not included in the assessment of our stated outcomes. 
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2.4 Results 
During the study accrual period a total of 85 patients provided consent to participate, with 
79 patients providing complete data for analysis. Baseline data is presented in Table 1. 
The cut-off value to define two QMLT groups at the 20th percentile was determined to be 
2.63cm. The range of QMLT was 1.09-6.50cm. 
 
A comparison of the outcome measures based on QMLT group is outlined in Table 2. 
Kolmogorov-Smirnov testing determined that LOS, PRA%, and creatinine at 1 month 
violated assumptions of normality and were therefore compared non-parametrically using 
Mann-Whitney U test. All other continuous variable satisfied assumptions of normality. 
 
The LOS over 14 days was significantly higher in those with lower QMLT.  Additionally, 
LOS was significantly longer in the low QMLT group (12.0 vs 8.0 days, p = 0.04). The 
difference in distribution for the type of donor (living, DCD, DBD) approached 
significance (p = 0.052), in favor of fewer living donors in the low QMLT group. The 
remaining demographic variables did not differ between the groups, nor did the 
secondary outcomes of rates of infection, rejection, or creatinine at one month. Notably, 
the breakdown of frailty phenotype scores did not differ between the groups (Table 2). 
Given that there was an apparent discrepancy in the rates of living donors between the 
low and high QMLT groups (7% vs 40%), we repeated the comparisons excluding living 
donor recipients. The results for this analysis are displayed in Table 3. When LOS was 
categorized into >14d or ≤14d, the difference was preserved (23% vs 0%, p = 0.01). The 
difference in mean LOS was no longer significant after exclusion of living donor 
recipients (12.0 vs 9.0 days, p = 0.22). This subsequent analysis carried a power 
calculated post hoc of 36%. 
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Multivariable analysis to assess for contributors of LOS was performed with entry of 5 
variables of interest: QMLT, Age, Graft function (delayed vs immediate), Frailty 
phenotype score, and Donor Type. Because LOS violated the assumptions of normal 
distribution, LOS was log-transformed for multivariable regression. Overall the model 
constructed was significantly predictive of LOS, with R2 = 0.33, F(5,74) = 8.89, p<0.001. 
The factors of deceased donor and presence of DGF conferred significant regression 
weight for greater LOS prediction (Table 4). 
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Table 1. Demographic and Outcome Data for Cohort of ESRD patients Undergoing 
Kidney Transplant 
 
Mean S.D./% 
N 79 
 
Age 49.9 14.4 
Gender (%M) 51 65% 
BMI 28.7 5.5 
QMLT (cm) 3.66 1.14 
20%ile QMLT 2.63 
 
LOS (days) 8.7 4.2 
Infection (N) 19 24% 
Rejection (N) 5 6% 
Frailty score (median) 1 
 
0 22 28% 
1 28 35% 
2 12 15% 
3 8 10% 
4 5 6% 
Unknown 4 5% 
DGF 17 22% 
Donor type 
  
LD 27 34% 
DBD 29 37% 
DCD 23 29% 
SCD 68 86% 
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ECD 11 14% 
Cr 1 month 138 91 
%PRA 25% 38% 
Transplant (KTx/SPK) 
(K(KTx/SPK) 
73/6 92%/8% 
* LD = Living Donor; DBD = Donation after Brain Death; DCD = Donation after 
Circulatory Death; SCD = Standard Criteria Donor; ECD = Extended Criteria Donor; 
DGF = Delayed Graft Function; KTx = Kidney transplant; SPK = simultaneous 
pancreas/kidney transplant; PRA = Panel Reactive Antibody; Cr = Creatinine; QMLT = 
Quadriceps Muscle Layer Thickness 
  
46 
 
 
Table 2. Outcome Data of ESRD Kidney Transplant Recipients Between Low and 
Higher QMLT Cohorts 
 
<20%ile 
QMLT 
>20%ile 
QMLT 
p value 
N 14 65 
 
Age (mean) 52.8 (15.3) 49.2 (14.1) 0.4 
Gender (%M) 11 (79%) 40 (62%) 0.36 
LOS 12.0 (7.4) 8.0 (2.8) 0.04 
LOS > 14d 3 (21%) 2 (3%) 0.04 
Infection 2(14%) 17(26%) 0.5 
Rejection 2 (14%) 3 (5%) 0.31 
DGF 29% 20% 0.65 
BMI 28.0 (5.8) 28.9 (5.6) 0.63 
LD 1 (7%) 26 (40%) 0.05 
DBD 8 (57%) 21 (32%) 
 
DCD 5 (36%) 18 (28%) 
 
SCD 11 (79%) 57 (88%) 0.3 
ECD 3 (21%) 8 (12%) 
 
Frailty score 
  
0.7 
0 3 (21%) 19 (31%) 
 
1 6 (43%) 22 (36%) 
 
2 3 (21%) 9 (15%) 
 
3 2 (14%) 6 (10%) 
 
4 0 (0%) 5 (8%) 
 
Cr 1 months 153 (98) 135 (90) 0.81 
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PRA 34 (44) 23 (35) 0.18 
QMLT 2.07 (0.44) 4.04 (0.90) 
 
KTx/SPK 12 / 2 61 / 4 
 
* LD = Living Donor; DBD = Donation after Brain Death; DCD = Donation after 
Circulatory Death; SCD = Standard Criteria Donor; ECD = Extended Criteria Donor; 
DGF = Delayed Graft Function; KTx = Kidney transplant; SPK = simultaneous 
pancreas/kidney transplant; PRA = Panel Reactive Antibody; Cr = Creatinine; 
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Table 3. Outcome Data of Low and Higher QMLT Cohorts after Censoring of 
Living Donor Transplant Recipients 
 
<20%ile 
QMLT 
>20%ile 
QMLT 
p value 
N 13 39 
 
Age (mean) 54.8 (13.7) 49.9 (15.4) 0.5 
Gender (%M) 10 (77%) 22 (56%) 0.324 
LOS 12.0 (7.4) 9.0 (2.6) 0.22 
LOS > 14d 3 (23%) 0 (0%) 0.01 
Infection 2 (15%) 11 (28%) 0.48 
Rejection 2(15%) 2 (5%) 0.26 
DGF 31% 33% 0.68 
BMI 28.3 (4.9) 29.5 (5.3) 0.31 
LD 0 (0%) 0 (0%) 0.63 
DBD 8 (62%) 21 (54%) 
 
DCD 5 (39%) 18 (46%) 
 
SCD 10 (77%) 31 (80%) 1.0 
ECD 3 (23%) 8 (21%) 
 
Frailty score 
  
0.77 
0 3 (23%) 11 (30%) 
 
1 5 (39%) 16 (43%) 
 
2 3 (23%) 7 (19%) 
 
3 2 (15%) 2 (5%) 
 
4 0 (0%) 1 (3%) 
 
Cr 1 month 155 (102) 146 (112) 0.89 
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PRA 37% (45%) 29% (38%) 0.4 
QMLT  2.05 (0.45) 4.00 (0.92) 
 
*All data are presented as N(%) or Mean (S.D.) 
**DBD = Donation after Brain Death; DCD = Donation after Circulatory Death; SCD = 
Standard Criteria Donor; ECD = Extended Criteria Donor; DGF = Delayed Graft 
Function; KTx = Kidney transplant; SPK = simultaneous pancreas/kidney transplant; 
PRA = Panel Reactive Antibody; Cr = Creatinine; 
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Table 4. Multivariable Regression Data for Length of Stay (log transformed) 
 
Unstandardized 
Coefficients 
Standardized 
Coefficients t Sig. 
95% Confidence Interval 
for B 
 
B Std. Error Beta 
  
Lower Bound Upper Bound 
(Constant) 1.742 0.219 
  
0 1.305 2.178 
QMLT -0.02 0.035 -0.056 0.95 0.566 -0.09 0.05 
Graft function 0.258 0.08 0.327 1.39 0.002 0.097 0.418 
Age 0.004 0.003 0.142 1.15 0.153 -0.001 0.009 
Living vs Deceased 0.25 0.087 0.305 1.36 0.005 0.077 0.423 
Frail vs Not frail -0.104 0.09 -0.111 0.89 0.253 -0.283 0.076 
*Graft function refers to delayed graft function compared to immediate graft function 
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2.5 Discussion 
In this prospective cohort study of kidney and kidney-pancreas transplant recipients, the 
QMLT was used as a novel assessment tool for identifying patients at risk for prolonged 
length of stay in hospital.  Overall, those with a low QMLT, defined as measuring below 
the 20%ile of the cohort, demonstrated a significantly greater proportion with LOS over 
14 days (21% vs 3%, p = 0.04), as well as longer mean length of stay in hospital (12.0 vs 
8.0 days, p = 0.04). 
 
This difference in LOS may be due to QMLT being representative of frailty. Frailty 
prevalence was 16% overall (defined as a Frailty Phenotype score > 2). This is lower than 
other recent reports of frailty incidence in those undergoing kidney transplant, suggesting 
our population may be more robust than other series of kidney transplant recipients 
examined for frailty.8 The components of the Frailty Phenotype include weight loss, slow 
walking speed, exhaustion, reduced activity, low hand grip strength.2 Given these 
measures are derivatives of skeletal muscle use, it stands to reason that frailty may be 
coexistent with significant loss of skeletal muscle mass and thus could be reflected in the 
observed quadriceps muscle layer thickness if enough mass was lost overall.  In 
community-dwelling elderly and critically ill populations, QMLT has been shown to 
moderately correlate with lower limb and total fat-free mass derived from whole body 
assessments.6,9   
 
Frailty has been associated with longer length of stay after transplant.  McAdams-
DeMarco (2017) utilized SRTR data linked to local institutional data to create a hybrid 
registry-augmented regression model to precisely estimate the impact of several donor 
and recipient factors with the ability to estimate the influence of frailty.3 Through this 
analysis, frailty conferred a 1.6-fold higher risk of being hospitalized greater than 2 
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weeks after transplant. We also observed that lower QMLT was associated with a higher 
risk of LOS > 14 days. We did not observe an association between Frailty Phenotype 
score and LOS on either pooled analysis or on multivariable regression in our cohort. 
This may relate to the lower prevalence of frailty in our cohort which may limit the 
ability to adequately assess this relationship. With a greater number of patients powered 
to test the relationship between QMLT and Frailty phenotype, a clearer association may 
emerge. 
 
The rates of the secondary outcomes of infection, rejection, and creatinine at 1 month 
were not significantly different between low and high QMLT groups.  It was 
hypothesized that QMLT may represent a surrogate marker of frailty, thus representing a 
state of systemic inflammation and inability to withstand extra stressors.2,10 Given the 
known derangements of inflammatory markers such as IL-6 in frail populations, we 
hypothesized greater rates of infection and rejection.11 As a result, rates of the clinically 
relevant insults of infection and rejection were assessed according to QMLT group. 
QMLT in our cohort was not a robust discriminator of these events. There was a 
relatively low event rate of rejection overall (6%), thus a larger sample size may help 
better define the influence of QMLT on rejection.  Rates of readmission in larger series, 
often due to infection or rejection events, after kidney transplant have shown differential 
rates between the frail and non-frail in other reports.12 The attendant immunosuppression 
of all transplant recipients may suppress the influence of frailty on the ability to avoid 
clinical infection in smaller sample sizes, thus a larger study may be able to better clarify 
the prognostic ability of QMLT for these events. 
 
A significant driver of increased LOS in our cohort appears to be the type of donor and 
the presence of DGF.  The influence of donor type is first evident by the different rates of 
donor types between the low and high QMLT groups (Table 2). When LD’s were 
censored, the significance of the difference in mean length of stay was lost (12.0 vs 9.0 
days, p = 0.22), but the proportion of recipients remaining in hospital beyond 14d 
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remained significantly higher in the low QMLT group. Eliminating LD’s significantly 
reduced the numbers in each group and this analysis was subsequently under powered to 
detect a difference in mean LOS. It has been shown in other reports that frailty 
significantly increases the risk of LOS beyond 14d after kidney transplant.3 The similar 
influence of QMLT supports this measure as being potentially indicative of frailty. 
 
The significant impact of donor type on LOS is further clarified by a multivariable 
regression analysis model using age, graft function, type of donor, frailty status, and 
QMLT as predictors of LOS.  Although both donor type and graft function significantly 
contributed to regression estimates, this model accounts for only 33% of the residual 
variation, confirming other factors not included in this model have appreciable influence 
on LOS. It may be that with greater numbers, QMLT may demonstrate a clearer influence 
on LOS, and our sample size was not adequate for logistic regression to assess the odds 
for LOS >14d. 
 
Given that DGF involves dialysis within the first week of transplant, a longer stay in 
hospital seems natural while waiting to define the progression and trajectory of renal 
function. DGF has been associated with longer LOS after renal transplant in other series 
as well.3 Even in the absence of DGF, deceased donor transplants may display higher 
rates of “slow graft function”, or a less than ideal improvement in renal function without 
requiring dialysis. This logically leads to longer stays in hospital and has also been 
demonstrated in larger series.3  
 
QMLT is a direct measure of one muscle compartment. Although it was predictive of 
prolonged LOS, it may not be sensitive enough to adequately reflect clinical frailty.  
Rather, QMLT may more clearly represent a measure of sarcopenia, or pathologic loss of 
muscle mass. Sarcopenia is likely a part of the underlying pathophysiology of frailty.10,11 
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The current study was not structured to assess the relationship between QMLT and 
sarcopenia, but this concept is explored in subsequent chapters. 
 
The discrepant rates of donor types in the low and high QMLT groups may also 
underscore an unappreciated bias in selecting patients for transplant.  It is possible that 
QMLT may be correlated to some other factor not captured within this study that reduces 
a patient’s likelihood of having or being approved for a living donor transplant. This is 
another area deserving of further study. 
 
This prospective cohort study represents one of the first to examine QMLT in the renal 
transplant population, with preliminary suggestion that QMLT may relate to LOS in 
hospital.  There are significant limitations to this study. The current study was powered to 
detect meaningful differences in LOS and allow for multivariable regression, however the 
relatively small sample size prevented meaningful subgroup analysis.  Further, QMLT 
provides a metric of muscle size, but it does not measure muscle quality.  Fat infiltration 
of the muscle may be evident subjectively during US assessment of the QMLT by 
making the muscle appear brighter, but in our current model of QMLT assessment, 
qualitative assessment of muscle is not incorporated. Future studies investigating the 
utility of QMLT should consider integrating muscle quality into QMLT assessment.  
Lastly QMLT measures one compartment of the appendicular musculature, and further 
research is needed to validate this measurement as a marker of sarcopenia in this 
population. 
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Chapter 3  
3 The Relationship Between Quadriceps Muscle Layer 
Thickness and Sarcopenia in the End Stage Renal 
Disease Population 
3.1 Introduction 
Sarcopenia and frailty are two related but distinct conditions affecting the elderly and the 
renal failure population of all ages.1 Reports have shown that age alone is not enough to 
adequately discriminate the presence of these conditions, especially in those with end 
stage renal disease (ESRD).2  The importance of sarcopenia and frailty in the ESRD 
population is gaining appreciation, with longer lengths of stay, higher re-admission rates, 
and worse mortality after kidney transplantation.3,4 
 
The quadriceps muscle layer thickness (QMLT) represents an emerging form of bedside 
assessment of muscle mass of the lower thigh, with validation in the critically ill, 
community dwelling elderly, and healthy populations.5-8  The QMLT has the potential to 
serve as a relatively inexpensive screening tool for identifying patients at risk of low 
muscle mass and potentially sarcopenia and frailty. 
 
There is currently a lack of studies examining the utility of QMLT in the ESRD and renal 
transplant population.  Current consensus guidelines recommend sarcopenia be diagnosed 
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based on functional assessment as well as total muscle mass assessment, the latter often 
requiring specialized equipment.9  QMLT has the potential to serve as a tool to detect 
cases of low muscle mass/frailty in this population. 
 
3.2 Purpose and Hypothesis 
The purpose of this study is to assess the relationship between QMLT in the ESRD 
population presenting for transplant and the presence of sarcopenia and frailty. 
 
It was hypothesized that the QMLT would be associated with measures of sarcopenia as 
defined by the European Working Group on Sarcopenia in Older Persons (EWGSOP2) 
criteria. 
 
3.3 Methods 
This is a prospective observational cohort study performed at London Health Sciences 
Centre University Hospital in Ontario, Canada.  Patient recruitment occurred from March 
1, 2019 until Jan 1, 2020, where all patients presenting for a kidney or combined kidney-
pancreas transplant were invited to participate. Patients were excluded if they were under 
18 years of age, receiving a concurrent liver or heart transplant, had an implanted 
defibrillator, or refused to participate. Upon recruitment, patients provided written 
informed consent to participate, at which point data collection occurred which included, 
age, gender, BMI, type of donor (donation after brain death [DBD], donation after 
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circulatory death [DCD], living donor [LD]), physical frailty phenotype scores (which 
includes hand grip strength and walking speed), quadriceps muscle layer thickness 
(QMLT), and bioimpedance analysis (BIA). 
 
QMLT is a measurement of the anterior thigh compartment musculature comprising the 
rectus femoris muscle and the vastus intermedius muscle.  Point of care ultrasound (BK 
technology) was used to quantify this value. With the patient in the supine position and 
feet pointed forward, a tape measure was used to measure the distance from the anterior 
superior iliac spine to the superior border of the patella, and the halfway point was 
marked with indelible ink on the anterior aspect of the thigh in the midline of the lower 
limb.  A curvilinear probe set to 6Hz in B-mode and with ample ultrasound jelly assessed 
this point of the thigh musculature. The image depth was adjusted so femur and 
superficial adipose were visible at the bottom and top of the ultrasound image, 
respectively.  Light pressure was applied to observe tissue dispersion to confirm the 
discrimination of the visible layers as muscle versus adipose. Pressure was released to the 
point of minimal pressure from the probe, allowing contact with the probe to the skin 
with no external compression applied. The image was then frozen, and electronic calipers 
measured the vertical distance from the inner layer of the rectus femoris muscle fascia to 
the level of the femur periosteum to obtain the QMLT.  This measurement was repeated 
for a total of three measurements and then repeated on the contralateral thigh.  The mean 
value of the six measurements obtained comprised the patient’s QMLT value. 
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Biompedance analysis (BIA) was performed using a Biomarkers 1500 Body Scan 
Analyzer (©Biodynamics Corporation), utilizing 50kHz current of 1mA. Patients were 
assessed in the supine position with electrodes place on the dorsum of the right hand and 
right foot.  Output from the BIA included tissue resistance, reactance, and phase angle. 
The raw values were used to compute total skeletal muscle mass according to the formula 
by Janssen et al (2000), which takes into account patient age (years), height (cm) and 
gender (male = 1) as well as BIA parameter Resistance (R):  
 
Skeletal muscle mass (kg) = [(Height2/R x 0.401) + (gender x 3.825) + (age x -0.071)] + 5.102 
 
Total skeletal muscle mass was indexed to the square of the patient’s height to derive the 
skeletal muscle mass index (SMI). An SMI < 10.76kg/m2 for males and <6.7kg/m2 for 
females defined low muscle mass, as per EWGSOP recommended cut-offs.10  
 
Hand grip strength was measured using a Jamar dynamometer using the dominant hand 
in a seated position with the elbow at 90°.  Three measurements were taken with the 
highest value constituting the hand grip strength.  Walking speed was assessed by having 
patients walk 15 feet timed with a stop watch. This was repeated once and the average 
times were used to calculated the average walking speed (m/s). 
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Sarcopenia was defined according the EWGSOP2 criteria.9 The incipient criteria for 
sarcopenia was hand grip strength below 27kg for males and 16kg for females. If this 
criterion was met, then the presence of either walking speed <0.8m/s (indicating poor 
muscle performance), and/or the presence of low SMI (indicating low muscle mass) 
defined a case of sarcopenia.  Patients were then categorized as either sarcopenic or non-
sarcopenic. Demographic data and mean QMLT values were recorded. Kolmogorov-
Smirnov testing assessed for assumptions of normal distribution of data. Data was 
compared between the groups using a two-tailed t-test or Mann-Whitney U test for 
continuous data where appropriate, and Chi-square or Fisher exact testing for categorical 
data with an alpha of 0.05.  A receiver operator curve was constructed to identify the 
performance of QMLT in predicting the presence of sarcopenia and SMI below gender-
stratified cut-offs as binary conditions. 
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3.4 Results 
A total of 79 patients met criteria for inclusion in the study and were analyzed for 
demographic data and is shown in Table 5. The group was divided by gender to allow for 
a stratified assessment of sarcopenia. Kolmogorov-Smirnov testing confirmed 
satisfaction of normal distribution for all continuous variables except for hand grip 
strength and this variable was thus analyzed non-parametrically.   
 
Other than hand grip strength and skeletal muscle mass index (SMI), the male and female 
subgroups did not differ in measured variables (Table 6). The incidence of low gender-
stratified hand grip strength, the primary criteria for determining sarcopenia, was similar 
between the males and females (20% vs 21%, p =0.85). Males showed a higher incidence 
of low SMI compared to females, but a similar proportion scored slow walking speed 
(<0.8m/s).  The incidence of sarcopenia was not significantly different between the 
groups. QMLT measurements did not differ by gender.  
 
When considering patients with complete data to assess QMLT, demographics and 
presence of sarcopenia, 74 patients had complete data for analysis (Table 7). The mean 
age of those with sarcopenia was significantly higher than those without (60.6 [12.5]yr vs 
47.8[13.7]yr, respectively, p = 0.01). The mean QMLT value did not significantly differ 
between those with or without sarcopenia (3.19 [0.90]cm vs 3.74[1.14]cm, respectively, p 
= 0.17) 
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The performance of QMLT as a screening tool for sarcopenia, low SMI, and frailty was 
tested using receiver operator curve analysis (Figures 10, 11).  The area under the curve 
(AUC) for QMLT predicting the presence of sarcopenia was 0.64 with 95% CI of (0.47-
0.82), p = 0.17. The AUC for QMLT detecting low SMI was 0.68 with 95% CI of (0.52-
0.85), p = 0.04.  Regarding frailty prediction, QMLT was not predictive of clinical frailty 
with an AUC of 0.52 (95%CI 0.35-0.68) p = 0.85; QMLT was not predictive of either 
low hand grip strength (AUC = 0.60 95%CI [0.44-0.76]) or slow walking speed (AUC = 
0.54 95%CI [0.38-0.70]). 
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Table 5. Demographic and Baseline Data for Entire Cohort 
Values expressed as Mean (SD) or N (%) 
 
N 79 
Age 49.9 (14.3) 
QMLT 3.66 (1.14) 
QMLT <20%ile 14 (18%) 
BMI 28.7 (5.5) 
HGS  33.5 (13.2) 
Male 51 (65%) 
Sarcopenia 10 (13%) 
Frail 17 (22%) 
Donor 
 
LD 27 (34%) 
DBD 29 (37%) 
DCD 23 (29%) 
ECD 11 (14%) 
KTx 73 (92%) 
SPK 6 (8%) 
Slow walk time 18% 
Low SMI 24% 
SMI kg/m^2 11.2 (2.6) 
* LD = Living Donor; DBD = Donation after Brain Death; DCD = Donation after 
Circulatory Death; SCD = Standard Criteria Donor; ECD = Extended Criteria Donor; 
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DGF = Delayed Graft Function; KTx = Kidney transplant; SPK = simultaneous 
pancreas/kidney transplant; Cr = Creatinine; QMLT = Quadriceps Muscle Layer 
Thickness 
 
Table 6. Comparison of Demographic and Outcome Measures Between Male and 
Female Recipients 
 Male Female P - value 
N 48 26  
Age 50.0 (14.0) 49.6 (15.3) 0.92 
QMLT 3.63 (1.16) 3.71 (1.11) 0.76 
QMLT <20%ile 11 (22%) 3 (11%) 0.23 
BMI 29.2 (5.6) 27.9 (5.2) 0.28 
HGS 38.7 (12.9) 23.9 (6.8) <0.001 
Sarcopenia 7 (15%) 3 (12%) 0.72 
Frail 6 (12%) 7 (27%) 0.10 
Donor   0.74 
LD 19 (37%) 8 (29%)  
DBD 18 (35%) 11 (39%)  
DCD 14 (28%) 9 (32%)  
ECD 5 (10%) 6 (21%) 0.14 
KTx 48 (94%) 25 (89%) 0.66 
SPK 3 (6%) 3 (11%)  
Slow walk time 30 (64%) 12 (57%) 0.60 
Low SMI 14 (32%) 1 (5%) 0.03 
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SMI kg/m^2 12.0 (2.19) 9.26 (2.40) <0.001 
Low HGS 10 (20%) 6 (21%) 0.85 
    
* LD = Living Donor; DBD = Donation after Brain Death; DCD = Donation after 
Circulatory Death; SCD = Standard Criteria Donor; ECD = Extended Criteria Donor; 
DGF = Delayed Graft Function; KTx = Kidney transplant; SPK = simultaneous 
pancreas/kidney transplant; Cr = Creatinine; QMLT = Quadriceps Muscle Layer 
Thickness 
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Table 7. Comparison of Sarcopenic and Non-Sarcopenic Groups 
  Sarcopenic Non-Sarcopenic P-value 
N 10 64   
Age 60.6 (12.5) 47.8 (13.7) 0.01 
QMLT 3.19 (0.90) 3.74 (1.14) 0.17 
BMI 28.5 (5.5) 31.6 (4.9) 0.11 
Frail 3 (30%) 13 (20%) 0.44 
QMLT<20%ile 3 (30%) 10 (16%) 0.36 
QMLT = Quadriceps Muscle Layer Thickness 
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Figure 12. ROC assessing QMLT as a Predictor of Sarcopenia 
 
Figure 13. ROC assessing QMLT as a predictor of low Skeletal Muscle Index 
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3.5 Discussion 
In this prospective cohort study of patients with ESRD presenting for kidney or combined 
kidney-pancreas transplant, the QMLT measurement emerged as a poor predictor for the 
presence of sarcopenia and frailty.  However, the QMLT did demonstrate a significant 
AUC for the prediction of low SMI as assessed from BIA estimates (AUC = 0.68, p = 
0.04).  
 
Sarcopenia was assessed according to the EWGSOP2 consensus on sarcopenia criteria 
where low hand grip strength (stratified by gender) was the primary indicator of possible 
sarcopenia, and confirmed with either the presence of low walking speed (<0.8m/s), 
and/or low muscle mass assessed by whole body skeletal muscle mass index (also gender 
stratified).9 The prevalence of sarcopenia was 13% overall, with 12% of males and 15% 
of females presenting as sarcopenic at the time of transplant. These numbers are in 
keeping with other reports of sarcopenia prevalence in the ESRD population, with rates 
of 5.8% to 30.6% cited in the literature, using varying methods of assessment.1 
 
QMLT represents an emerging measurement of muscle mass in the ESRD population, 
and was thought to possibly serve as a source of bedside screening for the diagnosis of 
sarcopenia. A significant proportion of the body’s overall muscle mass can be found in 
the region of the thighs, justifying the targeting of this region as a surrogate measurement 
70 
 
of total muscle mass.11 Berger and colleagues (2015) showed that in healthy community 
dwelling individuals, QMLT values correlate with lower limb fat free mass (r = 0.74), as 
well as total fat free mass derived from DEXA analysis (r = 0.71).7  In the critically ill, 
Paris et al (2017) showed in a critically ill population that QMLT demonstrated moderate 
correlation with the cross-sectional area of the abdominal musculature at the L3 level (r = 
0.45).8  This relationship overall was largely driven by the young males, whereas the 
correlation in young females, elderly females, and elderly males was not significant (r = 
0.13, 0.24, 0.26, respectively).8  This suggests that QMLT may be applicable as a 
surrogate measure in select populations. We found reasonable concordance between 
QMLT and SMI, a measure of whole body muscle mass, but this relationship was not 
seen regarding sarcopenia. 
 
Several possible reasons may explain the lack of strong association between QMLT and 
sarcopenia.  Firstly, QMLT measures a single compartment of an appendicular muscle 
group (anterior thigh).  While this muscle group is important for locomotion, rising from 
sitting, and balance, other muscle groups play significant roles in function as well, but are 
not directly measured by the QMLT. In addition, muscle function defines sarcopenia, 
with low muscle mass being a potential component.9 Changes to muscle mass reflected in 
the QMLT may occur at a later time-point in sarcopenic progression, or distribution of 
muscle loss may vary based on gender or age. Another consideration is that QMLT 
measures the thickness of the muscle groups but not the total cross-sectional area of the 
muscles of interest. Cross-sectional area may provide a better estimation of muscle mass 
in the lower limb.  In the healthy adult population undergoing resistance training, thigh 
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muscle thickness on ultrasound had moderate correlation with changes in muscle cross-
sectional area on MRI (r = 0.69) after training, suggesting the muscle thickness alone is 
probably a reliable index of muscle cross-sectional area at a given landmark. Thus, 
measurement of QMLT versus cross-sectional area likely will not significantly impact the 
relationships observed. Other groups have utilized multiple sites of ultrasound 
measurement to estimate whole body skeletal muscle, including multiple areas of the 
thigh and the upper arm, to increase the validity of ultrasound assessments of the 
appendicular muscles.8 Lastly, QMLT does not provide a qualitative measure of muscle.  
Myosteatosis, or fatty infiltration of the muscle, as well as fibrous infiltration of muscle, 
results from muscle disuse and weakness, but does not necessarily compromise gross 
approximations of size. Therefore, a muscle with significant myosteatosis may have 
significantly worse functional potential compared to a similarly sized muscle with 
minimal steatosis.22 
 
Consideration should be given to potential population specific factors, such as fluid status 
affecting QMLT measurements. Given that impaired management of fluid volume status 
is a feature of ESRD, it is possible that muscle may swell/contract with 
hyper/hypovolemic states which could vary from patient to patient depending on 
adequacy of recent dialysis, dialysis modality, etc. Sabatino et al (2017) assessed the 
reliability of QMLT measurement using bedside ultrasound in the critically ill population 
with concurrent dialysis dependent severe acute kidney injury. In this cohort, when 
QMLT measurements were compared pre- and post-dialysis, values did not significantly 
differ.  This observation was preserved regardless of whether conventional 4-hour 
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dialysis or sustained low-efficiency dialysis (6-12 hours) was used, nor did degree of 
weight change after dialysis impact QMLT measurements.12 The fluid shifts experienced 
in the cohort of Sabatino and colleagues ranged from -0.5 to -3.0kg.  In another cohort of 
ESRD patients on hemodialysis, pre- and post-dialysis QMLT values did not significantly 
differ.  Thus it appears that fluid shifts likely do not impact the assessment of QMLT. 
 
We found in our cohort of kidney and kidney-pancreas transplant recipients a prevalence 
of sarcopenia of 13% overall (12% in males; 15% in females).  This rate is in keeping 
with or slightly lower than other published reports on sarcopenia in the transplant 
population. Ozkayar et al (2014) showed in a cohort of patients who already received a 
kidney transplant that sarcopenia was a prevalent in up to 20%, with a mean age of 44 in 
the sarcopenic group and 36 in the non-sarcopenic recipients. Patients were assessed by 
hand grip strength using weight based cut-offs from the Cardiovascular Health Study, and 
BIA derived fat-free mass (not muscle mass per se).13   
 
Fluid status is an important factor in BIA assessment. The resistance value provided by a 
BIA analyzer is a measure that is inversely related to body water content.14-16 While raw 
outputs from a BIA analyzer have been shown to be useful in predicting skeletal muscle 
mass, the concordance of prediction equations to gold standard referent values may be 
altered by significant fluctuations in total body water.17  Hydration status impacts the 
measured resistance, and overhydration may mask muscle atrophy.1,18  Our protocol did 
not standardize the timing of BIA analysis in relation to hemodialysis runs or peritoneal 
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dialysis dwells due to practicalities of data acquisition, potentially reducing the internal 
validity of this assessment. However, patients were assessed immediately prior to kidney 
transplant whenever possible.  Proceeding to the transplant operation typically requires 
draining of the peritoneal dialysis fluid and displaying no acute indications for dialysis. 
Therefore, it is thought the risk of underestimation of muscle mass may be minimal. 
 
Another consideration is interobserver variability of QMLT measurement.   QMLT 
comes from point of care ultrasound measurement, and therefore is susceptible to 
variability depending on the observer.  Hadda et al (2017) sought to quantify the intra- 
and inter-observer reliability of the QMLT assessed by ultrasound in the pneumosepsis 
population and found that the intraclass coefficient (ICC) of the intraobserver variability 
ranged between 0.835 and 0.925, with interobserver variability ICC of 0.992.19 Although 
we did not specifically test for interrater reliability in our cohort, several reports have 
demonstrated this modality to be reproducible across both expert and novice 
assessors.20,21 Future studies using the QMLT in the kidney transplant population should 
ensure measures of interrater reliability to add confidence to the internal validity in this 
population. 
 
The optimal mode of assessment for sarcopenia in the ESRD population remains in 
evolution.  The QMLT may not be a definitive stand-alone tool to replace other validated 
clinical assessment instruments of sarcopenia, but could play a role in the armamentarium 
of overall risk stratification of transplant recipients. Further study should be given to the 
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various forms of identifying sarcopenia to validate the QMLT and other currently 
available modalities in this population. 
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Chapter 4  
 
4 Comparing Metrics of Sarcopenia and Muscle Mass in 
the Renal Transplant Population – Assessment of Test 
Performance and Agreement 
4.1 Introduction 
Sarcopenia, or pathologic loss of muscle, in the end stage renal disease (ESRD) 
population has been recognized as prevalent and has significant implications on the long 
term outcomes of those on dialysis as well as those undergoing transplant.1, 2 Larger 
muscle mass at the time of transplant has been suggested to portend improved survival 
after transplant.1 Although there exists consensus criteria by several international 
working groups, the most commonly cited diagnostic criteria for the diagnosis of 
sarcopenias is that of the EWGSOP2.3 A drawback of the EWGSOP2 criteria is that 
reviewed studies in the literature have largely excluded the renal failure/dialysis 
dependent population. In the realm of renal transplant, there is a paucity of data reporting 
on measures of muscle mass and function to confidently apply widely accepted criteria to 
this population. 
 
In previous chapters, the EWGSOP2 criteria was applied to a prospective cohort of renal 
transplant recipients to detect the presence of sarcopenia, however no instruments have 
been validated specifically in this population.  The QMLT has demonstrated association 
with prolonged length of stay in hospital, as well as shown discrimination for estimates of 
low overall muscle muscle mass. Some of the metrics used for ascertaining sarcopenia 
have been applied as part of frailty testing with good validity, namely grip strength and 
walking speed.4, 5  
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Cross-sectional imaging in the form of whole body CT or MRI has been considered a 
gold-standard reference for quantifying skeletal muscle content.3, 6 Whole body MRI or 
CT is costly, carries extra risk, and is not universally available.  Segmental assessment of 
the body’s compartments, such as the mid-thigh, arm, or torso7 may serve as surrogate 
measurements that correlate with total body skeletal muscle.  However, these forms of 
imaging have the drawback of being outside of usual clinical practice and thus may suffer 
from the same drawbacks as whole body imaging. 
 
4.2 Purpose and Hypothesis 
The purpose of this chapter is to compare the agreement between different modalities of 
sarcopenic assessment in the ESRD population undergoing transplant, including muscle 
mass and functional assessments currently endorsed by the EWGSOP2 criteria as well as 
the quadriceps muscle layer thickness (QMLT). 
 
It was hypothesized that cross-sectional area (CSA) of the entire abdominal musculature 
at L3 as well as psoas muscles would correlate with total body skeletal muscle index 
(SMI) as determined by bioimpedance (BIA) analysis as well as QMLT. 
4.3 Methods 
This study involved a prospective observational cohort study performed at London 
Health Sciences Centre University Hospital in Ontario, Canada.  Accrual of patients 
occurred from March 1, 2019 to Jan 1, 2020. All patients presenting for a kidney or 
combined kidney-pancreas transplant were invited to participate, and were excluded if 
under 18 years of age, had a pacemaker, were due to receive a concurrent liver or heart 
transplant, or did not agree to participate.  Participants had demographic data collected 
which included age, gender, height, weight, BMI, type of donor, as well as clinical 
assessment values related to the physical frailty phenotype described previously8, in 
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addition to bioimpedance assessment used to derive whole body skeletal muscle mass.9  
QMLT was measured as well according to the protocol described earlier in  Chapter 2 
and 3.  
 
When CT scans of the abdomen and pelvis were available for recipients, these images 
were analyzed for skeletal muscle mass.  CT image data sets were imported from AGFA 
Healthcare PACS (Version 8.1.2) into Aquarius Intuition Viewer (Version 4.4.13.P2 - 
TerraRecon) to perform body composition analysis. Two consecutive axial image slices 
at L3 vertebral level were selected for analysis. Skeletal muscle cross-sectional areas 
(cm2) for each CT slice were measured by summing the appropriate density pixels in the 
areas of interest. Two different areas of interest were utilized for analysis. In the first, 
segmentation of all the skeletal muscles on an axial slice was performed; this included the 
erector spinae, quadratus lumborum, psoas, internal and external obliques, transverse 
abdominus, and rectus abdominus muscles. In the second, segmentation of the bilateral 
psoas muscles alone was performed. Boundaries for the two areas of interest were 
manually defined for each slice by a subspecialty-trained musculoskeletal radiologist. A 
CT Hounsfield unit (HU) range of -29 to +150 was used to defined skeletal muscle. 
Measurements of the cross-sectional area of skeletal muscle for both the “total muscle 
cross-sectional area” (CSAAbdoL3) and “psoas cross-sectional area” (CSAPsoasL3) were 
performed for each axial slice and then an average of the two slices was obtained for each 
of the respective cross-sectional areas (Figure 14). 
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Figure 14. Representative CT image at L3 showing definition of area of interest and 
area of muscle identified by TerraRecon software based on HU parameters of -29 to 
150. A. Psoas cross-sectional area, B. Total abdominal cross-sectional area 
 
CT images were not obtained for the purposes of research. All CTs were done in the 
context of clinical indication to assess vascular or intraabdominal organ anatomy to aid in 
surgical preparation for transplant or assess patients for cause. CT images obtained in the 
peri-transplant period (upon admission, post-operative) were deemed eligible for 
inclusion in the analysis as it was considered that these perioperative images would still 
provide reliable representations of the skeletal muscle mass possessed by recipients at the 
time of transplant.  CT images were not included in the analysis if the L3 region was 
incompletely imaged, edema was too significant to reliably distinguish regions of interest 
for muscle area determination, or defects in the abdomen were present due to surgical 
complication (such as CT done for massive dehiscence obscuring the contours and 
boundaries of the abdominal wall musculature). 
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Statistical analysis was performed using SPSS v 26.0. Kolmogorov-Smirnov testing 
assessed for the assumption of normality of the analyzed data.  Demographic data was 
collected relating to age, gender, and presence of sarcopenia. These values were 
compared between gender groups using unpaired t-test and Fisher exact testing where 
appropriate. The primary analysis was construction of a correlation matrix of the various 
measures contributing to the assessment of sarcopenia according to the EWGSOP2 
criteria. When variables satisfied assumptions of normality Pearson correlation was used, 
and when normality assumptions were violated the Spearman correlation was employed. 
The variables included measures of muscle function (hand grip strength, time to walk 15 
feet converted to walking speed), muscle mass (skeletal muscle index [SMI] derived from 
bioimpedance analysis9), CSAPsoasL3, CSAAbdoL3, as well as the QMLT. Receiver-
Operator Curve (ROC) analysis was performed to assess the performance of the CT 
derived metrics in predicting the presence of sarcopenia. Sarcopenia was deemed present 
when low HGS based on gender-stratified cut-offs was identified, and the presence of 
either slow walking speed (<0.8m/s) or low skeletal muscle mass based on accepted SMI 
cut-offs.3, 6 Finally, the agreement between CT metrics (CSAPsoasL3/AbdoL3) and the 
classification of low SMI and sarcopenia was assessed using a Kappa score for each test. 
Cut-offs of the 25th and 50th percentile for both CT metrics were tested for agreement 
with the classification of low SMI (based on the threshold for sarcopenia classification), 
as well as for sarcopenia itself. Alpha was set to 0.05 for all analyses. 
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4.4 Results 
Forty four of 79 patients in our observational cohort had CT scans of the abdomen/pelvis 
performed prior to, or shortly after their transplant, that were of adequate quality for 
assessment. Table 8 contains the gender stratified values of CT metrics and rates of 
sarcopenia. Fewer females were sarcopenic numerically, however this did not meet 
statistical significance. The median time between CT scan and transplant was 56 days 
prior to transplant, with 14 of 44 having a CT performed greater than 6 months 
beforehand (range 187-602 days pre-transplant), while 16 of 44 had a CT performed after 
the transplant (range 1-130 days post-transplant). The remaining patients’ CT scans were 
performed between 1 and 167 days before surgery (median = 63 days). 
 
Table 8. Gender stratified values of age and CT derived metrics of muscle mass at 
L3 and sarcopenia 
  Male Female p-value 
N 30 14  
Age (yr) 51.4 (13.6) 50.2 (14.5) 0.79 
CSA Abdo L3 (cm2) 159.9 (28.7) 114.8 (22.6) <0.001 
CSA Psoas L3  (cm2) 22.6 (5.6) 14.2 (2.7) <0.001 
Sarcopenia (%) 6 (20%) 1 (7%) 0.65 
Values for Age and CSAAbdo/PsoasL3 are presented as mean (S.D.) 
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All 30 males had both CT and adequate data to classify sarcopenia, while only 8 of 14 
females had complete data. Subsequent analysis was only completed for the males in the 
cohort due to lack of assessable data in female participants. 
 
Table 9 displays a correlation matrix comparing the univariate correlation of the 
individual components of sarcopenia classification, the CT derived metrics, and the 
QMLT. Hand grip strength (HGS) was significantly correlated with gait speed/walk time, 
CSAPsoasL3, and CSAAbdoL3. CSAAbdoL3 was most strongly correlated with the CSAPsoasL3, 
and was followed by total body SMI derived from BIA parameters. QMLT showed no 
significant correlation to any of the sarcopenia/CT parameters. 
 
Table 9. Correlation matrix of sarcopenia parameters, CT measures of muscle mass, 
and QMLT 
 HGS Walk time SMI CSA Psoas L3 CSA Abdo L3 
CSA 
QMLT 
HGS 1.0 - - - - - 
Walk Time -0.34** 1.0 - - - - 
SMI 0.25 0.08 1.0 - - - 
CSA Psoas L3 
CSA 
0.57** 0.02 0.28 1.0 - - 
CSA Abdo L3 0.64** -0.01 0.51* 0.71* 1.0 - 
QMLT 0.08 -0.11 0.19 -0.02 0.14 1.0 
* indicates p<0.05 for Pearson correlation coefficient 
** indicates p<0.05 for Spearman correlation coefficient 
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Receiver-Operator Curve (ROC) analysis assessed the performance of the CT metrics in 
predicting sarcopenia. Table 10 contains the associated Area Under the Curve (AUC) 
values for both metrics as well as age, a known contributor to sarcopenia. The CSAAbdoL3 
demonstrated good performance in predicting the presence of sarcopenia with an AUC of 
0.81 (95%CI: 0.66-0.97, p = 0.02). CSAPsoasL3 and Age did not significantly predict 
sarcopenia, although age approached the level of significance. The ROC curves for the 
performance of CSAAbdoL3 is depicted in Figure 15 and 16. The non-significant ROC 
curves are not displayed. The cut-off point for optimal performance of CSAAbdoL3 was 
155cm2, which was associated with a sensitivity of 83% and a specificity of 74% for 
predicting sarcopenia. Changing the cut-off to 159cm2 (the median measurement) 
increased sensitivity to 100% while specificity decreased to 65%.  
 
Table 10. Areas under the curve for CT metrics and age for identifying sarcopenia 
and skeletal muscle index below gender-stratified cut-offs 
Variables AUC p-value 95% CI 
CSA L3 total : Sarcopenia 0.81 0.02 0.66-0.97 
CSA L3 psoas : Sarcopenia 0.52 0.87 0.25-0.79 
Age : Sarcopenia 0.72 0.06 0.50-0.95 
CSA L3 total : Low SMI 0.74 0.03 0.53-0.95 
CSA L3 psoas : Low SMI 0.48 0.88 0.26-0.71 
Age : Low SMI 0.50 0.97 0.29-0.70 
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Figure 15. Receiver operator curve of cross-sectional area of total abdominal 
musculature at L3 as a predictor of sarcopenia 
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Figure 16. Receiver operator curve of cross-sectional area of total abdominal 
musculature at L3 as a predictor of low skeletal muscle index 
 
 
 
The agreement between the CT metrics at the 25th and 50th percentile cut-offs and low 
SMI and sarcopenia was assessed using Kappa scores and is outlined in Table 11. The 
greatest agreement in testing occurred between the 25th percentile CSAAbdoL3 and low 
SMI, followed by the 50th percentile of CSAAbdoL3 and sarcopenia. Both Kappa values 
suggest modest agreement between the test modalities. 
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Table 11. Kappa statistics testing for the agreement between CT metrics of muscle 
mass at 2 cut-offs and sarcopenia, skeletal muscle index below gender-stratified 
thresholds 
Comparators Kappa p-value  
CSA L3 Psoas - 25%ile vs. Low SMI 0.054 0.76 
CSA L3 Psoas - 50%ile vs. Low SMI 0.096 0.8 
CSA L3 Total - 25%ile vs. Low SMI 0.53 0.003 
CSA L3 Total - 50%ile vs. Low SMI 0.37 0.04 
CSA L3 Psoas - 25%ile vs. Sarcopenia 0.11 0.55 
CSA L3 Psoas - 50%ile vs. Sarcopenia -0.13 0.44 
CSA L3 Total - 25%ile vs. Sarcopenia 0.31 0.096 
CSA L3 Total - 50%ile vs. Sarcopenia 0.44 0.004 
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4.5 Discussion 
In our prospective cohort of kidney/kidney-pancreas transplant recipients, the level of 
agreement between muscle mass assessment using CT scanning and other clinical 
measures of muscle mass and sarcopenia were compared. Cross-sectional area of the 
entire abdominal musculature at the level of L3 (CSAAbdoL3) correlated the best with non-
structural assessment of muscle (HGS) as well as other methods of muscle mass 
estimation (CSAPsoasL3, SMI derived from bioimpedance analysis). CSAAbdoL3 also 
showed good performance as a predictor of sarcopenia at a cut-off of 155cm2 carrying a 
sensitivity and specificity of 83% and 74%, respectively.  The good performance of CT 
was only demonstrable in males, however, owing to lower numbers of females with 
available CT scans. The reliability of CT in female transplant recipients remains 
unexplored in this population. On the other hand, QMLT did not significantly correlate 
with any of the metrics recommended for assessment of sarcopenia by the EWGSOP2 
criteria. 
 
The importance of sarcopenia has emerged in the context of solid organ transplants 
outside of kidneys. Hsu et al (2019) showed that sarcopenia in lung transplant recipients, 
defined as a psoas CSA indexed to height, significantly predicted 1, 2, 3, and 4 year 
mortality.10 To derive normative values, gender-based cut-offs were defined from their 
internal cohort based on scatterplot smoothing and spline modeling. van Vugt et al (2016) 
demonstrated in a systematic review and meta-analysis of liver transplant recipients that 
sarcopenia independently increased the risk of both wait-list and post-transplant 
mortality.11 Based on growing reports of the influence of sarcopenia in non-renal 
transplant populations, the importance of being able to identify sarcopenia in the renal 
population becomes evident.   
 
The impact of sarcopenia in renal populations has been highlighted in the literature. Lai 
et al (2019) described a sarcopenia prevalence of 49% in a prospective cohort study of 77 
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CKD patients, with half requiring renal replacement therapy in the form of dialysis.12 
They found that sarcopenia was significantly associated with increased intima-media 
thickness, a marker of atherosclerosis and cardiovascular risk and flow-mediated dilation 
of the brachial artery, a measure of endothelial dysfunction. Montreal Cognitive 
Assessment (MoCA) scores were significantly lower in the sarcopenic group and 
depression was more prevalent, suggesting a link between sarcopenia and cognitive 
decline and depression. These authors defined sarcopenia using HGS and Janssen’s 
SMI12, similar to our current study. Our prevalence of sarcopenia was much less than that 
reported by Lai and colleagues, possibly due to the older age of their cohort (mean age 
69). Despite divergent demographics, their findings suggest that sarcopenia may be an 
important factor to screen for in the ESRD/transplant population, beyond the concerns of 
perioperative/post-transplant outcomes. 
 
Kittiskulnam et al (2017) found in a prospective study that sarcopenia per se did not 
significantly impact the risk of mortality in a maintenance hemodialysis population of 
645 patients, nor did any measurement of muscle mass based on bioimpedance 
spectroscopy.13 Functional measures of muscle, including gait speed and grip strength 
(components of sarcopenia case definitions) did, however, significantly impact survival. 
The addition of any muscle mass covariates did not improve the predictive value of 
functional measures. These results emphasize the importance of functional measures of 
muscle. Giglio et al (2018), in an observational cohort study of 170 maintenance 
hemodialysis patients measuring muscle mass with BIA, found lower muscle strength and 
sarcopenia significantly increased the risk of experiencing hospitalization (aRR = 1.92 
and 2.08, respectively) as well as overall survival (aRR = 1.84 and 2.09, respectively).14 
These authors maintained case definitions of sarcopenia congruent with EWGSOP2 
criteria, utilizing appendicular skeletal muscle mass and HGS as defining criteria, 
however gait speed was not included. Lower muscle mass in isolation, however, was not 
significantly associated with either overall survival or hospitalization. 
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Hand grip strength in our cohort significantly correlated with another parameter of 
sarcopenic assessment: walking time. Additionally, HGS showed significant correlation 
to CSAL3Psoas and CSAL3total. Functional measures may seemingly offer cheaper and more 
accessible solution to screening for sarcopenia in the clinical setting than more expensive 
cross-sectional imaging. Chan et al (2019) longitudinally studied 128 kidney transplant 
recipients who were ≥1 year post transplant with a functioning graft, placing patients into 
a sarcopenic or non-sarcopenic group. The authors defined sarcopenia by the presence of 
both low HGS and low muscle mass based on population normative values provided by 
the manufacturer of the BIA machine used in their study. They found that at a median 
follow up of 64 months, low strength was independently associated with their composite 
endpoint of mortality or hospitalization, while neither low muscle mass nor sarcopenia 
were significantly predictive of these outcomes.15  The superior performance of grip 
strength supports the need for clinical testing of muscular function in this population. The 
apparent lack of prognostic significance seen by Chan et al. in relation to muscle mass is 
challenged by the case definitions of low muscle mass and sarcopenia.  Their surrogate 
measures of muscle mass were not derived from regression equations validated in the 
literature, nor were the EWGSOP2 or any other published criteria used to assess 
sarcopenia.  
 
The importance of standardizing or defining thresholds for muscle mass, as well as 
uniform agreement on case definitions of sarcopenia, are important. This was highlighted 
by Lamarca et al (2014) in a multicentre cross-sectional study, where a wide range of 
sarcopenia prevalence was found depending on the modality and cut-off implemented. 
With BIA + HGS derived case definitions, prevalence ranged from 12.7% to 45.1% with 
the BIA cut off at 20th%ile and 2 S.D. below young population norms, respectively.16 The 
BIA formula used to derive skeletal muscle mass estimations was not described, limiting 
the ability to confidently compare these authors’ findings to our own and others in the 
literature.   
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Whole body cross-sectional imaging is considered the gold-standard referent for 
measuring muscle mass6, but in its stead single slice images have been used in several 
research settings. One area of interest in cross-sectional imaging has been the psoas 
muscle as well as more expanded views of the abdominal musculature.10, 17, 18 We chose 
to examine both the psoas CSA and entire abdominal muscle CSA to explore the relative 
performance of both metrics.  
 
Morrell et al (2016) interrogated the performance of cross-sectional imaging in 
maintenance hemodialysis patients to predict low muscle mass. They used MRI at the 
level of the mid-thigh and the L4-5 level compared to whole body lean mass derived 
from DEXA measurement. Overall, total CSA of the mid-thigh was the greatest predictor 
of whole body lean mass, followed by psoas muscle cross-sectional area.18 Furthermore, 
these authors demonstrated that mid-thigh muscle CSA was highly correlated with psoas 
CSA at L4-5 (r=0.83), and the AUC for psoas CSA for predicting sarcopenia was 
between 0.81 and 0.92. Sarcopenia was defined using two different percentile cut-offs 
based on their cohort DEXA estimations of lean body mass, rather than EWGSOP2 
definitions, which rely on consideration of some measure of muscle function in addition 
to mass. Nevertheless, Morrell and colleagues show that psoas muscle CSA at L4-5 in the 
dialysis population was predictive of total muscle mass.  
 
Our results, however, did not support such a strong relationship between CSAPsoasL3 and 
total muscle mass. In fact, our data suggest that a relatively poor discriminatory capacity 
for psoas CSA to predict overall muscle mass with an AUC of 0.48.  The reasons for this 
discrepancy are several-fold. Firstly, we assessed psoas CSA at the L3 level which is 
higher than the level studied by Morrell et al.  This is relevant when one considers the 
mean CSA of the psoas in our population was 19.9cm2 (22.6cm2 males; 14.2cm2 females) 
while the mean CSA of the psoas in the report by Morrell was 10.4cm2. The difference 
between measuring at L3 vs L4-5 may have accounted for this variation, as the psoas 
tapers in circumference as it passes inferiorly to insert onto the lesser trochanter of the 
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femur. Whole body muscle mass was assessed in our study using regression equation 
based off BIA parameters validated in the literature for the general population with 
recommended cut-offs from the EWGSOP19, 20, whereas Morrell set cut-offs of the 10th 
and 25th percentiles of total lean body mass based on DEXA scans. Assessing the 
performance of any single slice image is clearly dependent on consistent case definitions. 
 
Shen, et al (2004) identified that in healthy subjects, the cross-sectional area of the entire 
abdominal musculature at a position of 5cm above the L4-5 level (approximately L3), 
was highly correlated with measures of total skeletal muscle volume using standardized 
whole body scans (Pearson correlation, r = 0.924).21 When other covariates were added 
into a multivariable prediction model, the addition of sex, age, BMI, and waist 
circumference only improved the R2 by 2.3-3.3%, suggesting the single-slice image may 
be used to represent total body skeletal muscle reliably.21 
 
Giglio et al (2019) looked at patients with chronic kidney disease (of which 70% were 
stage 3-4) using CT to derive CSA at the L3 level of the entire abdominal musculature 
and SMI using bioimpedance measures (using the Janssen formula). They found a Kappa 
of 0.41 and AUC of 0.70 (0.60-0.81), with r = 0.51 (Pearson correlation) in males 
comparing these two measurements.7 These results compare favorably to the reported 
outcomes of the current study.  Our population of end-stage renal patients undergoing 
transplant demonstrated CSAAbdoL3 provided an AUC of 0.74 (0.53-0.95), with r=0.51 on 
Pearson correlation. The concordance of this CT metric in both the pre-dialysis CKD 
population and ESRD population undergoing transplant supports the validity of this form 
of testing in renal populations, and supports the utility of CT-assessed muscle mass 
across several stages of renal disease.  
 
Quadriceps muscle layer thickness, an emerging measure of muscle mass in the literature, 
correlated poorly with functional components and structural components of sarcopenia 
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assessment (Table 9). The poor performance of QMLT as a predictor of sarcopenia was 
explored in Chapter 3. With minimal correlation between QMLT and CSAPsoasL3/AbdoL3, 
the enthusiasm to further explore this metric as a surrogate for sarcopenia becomes 
tempered. This finding is contrasted by other studies demonstrating high concordance 
between mid-thigh muscle area and psoas CSA.18 An important differentiator is that 
QMLT measures the thickness of the anterior compartment of the thigh (rectus femoris, 
vastus intermedius muscles), while other studies correlating the thigh and psoas have 
utilized cross-sectional area.18 Previous studies have demonstrated concordance of 
QMLT and psoas CSA on CT, however. This positive relationship has been demonstrated 
in the young male critically ill population, with poor correlation in critically ill females 
and the elderly.23  Thus, QMLT may have selective applicability to identify clinically 
vulnerable subpopulations. Expanded study of the QMLT in concert with other accepted 
metrics of sarcopenia are needed to better define this role. 
 
Another consideration that both total CSA and muscle compartment thickness do not take 
into account is the quality of the muscle, namely intramuscular fibrosis or adiposity from 
disuse/disease and other derangements of muscle architecture.22  Fukuda et al (2018) 
retrospectively assessed 41 pancreas transplant recipients with CTs done at the time of 
transplant for the presence of sarcopenia defined as a psoas muscle index (cross-sectional 
area indexed to height) at the level of the umbilicus below the lowest quantile in the 
cohort, and found that sarcopenia did not worsen the risk of complications or graft 
survival.17 These authors also assessed intramuscular adipose content on the same CT 
scans, and found that adipose content of the multifidus muscles significantly increased 
the odds of complications. The adipose content was only moderately associated with 
psoas muscle index (r = -0.51). Taken together, the relative importance of muscle quality, 
over and above the gross size in the form of cross-sectional area or volume, may underpin 
the imperfect relationship between sarcopenia and CT-derived metrics in the present 
study. In addition, the distinction of muscle quality may be a more telling metric to 
consider in future research.  
96 
 
 
This study does have significant limitations that require consideration. CT scans were not 
available for every patient, limiting our sample size for analysis. Systematic bias around 
those with and without indications for CT are not able to be accounted for because of 
this. Additionally, the date of CT scan and transplant were inconsistent across the cohort, 
introducing uncertainty to the findings, as the effect of time on changes to muscle mass 
are not accounted for due to lack of serial imaging. Paris et al (2017) found that QMLT 
was well correlated with CT derived measures of the psoas muscle in the critically ill 
when the QMLT and CT were done an average of 1 day apart.23  Bioimpedance analysis 
also carries inherent flaws as the values derived from BIA are influenced by hydration 
status, a significant consideration in the mostly dialysis dependent population undergoing 
transplant. Due to logistical constraints, timing of BIA was not standardized relative to 
dialysis runs and therefore may introduce variation in the results not able to be accounted 
for. On balance, a strength of our study is that we maintained validated case definitions of 
sarcopenia and cut-off values from the sarcopenia literature. This is also the first report to 
the authors’ knowledge of assessing metrics of sarcopenia/muscle mass in the ESRD 
population at the time of transplant. 
 
In summary, CTAbdoL3 demonstrated good predictive ability to identify sarcopenia. 
Further exploration of this metric in the kidney transplant population is warranted to 
better characterize population normative values as well as gender-specific thresholds to 
define low muscle mass for standardization in future studies. These measurements should 
be maintained within the context of muscular function, as is suggested by consensus 
guidelines on defining sarcopenia. With improved definitions to operationalize 
sarcopenia, the impact on clinical outcomes can be better studied and appreciated and 
opens the door to rational interventions to impact populations at risk. 
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5 General Conclusions and Future Directions 
The impact of frailty and sarcopenia in renal transplant recipients has been established in 
the literature, and is continuing to be refined over time. The literature has demonstrated 
that frailty, assessed using the Physical Frailty Phenotype, significantly affects recipient’s 
LOS, DGF rates, and influences survival, thus validating its use in the transplant 
population.1-3 Sarcopenia is intimately related to frailty, acting as either a component of 
the underlying pathophysiology of frailty or another manifestation of a common pathway 
with frailty. 
 
The QMLT has received attention in several contexts as an accessible surrogate measure 
of frailty and/or sarcopenia that appears to be reliable in published reports.4-7 Our use of 
the QMLT identified those at risk of longer LOS after transplant. It is possible that with 
greater numbers of participants to allow stratification by donor type, statistical power can 
be maintained to refine the influence of this metric on patient outcome. Further study of 
the QMLT in the transplant population should be undertaken to expand on this finding, 
and to refine the value of measuring the QMLT. We intend to expand on our number of 
participants. QMLT in isolation did not show good discrimination for the assessment of 
sarcopenia but was correlated with overall skeletal muscle mass using bioimpedance 
derived calculations. It is possible this observation relates to the functional assessment 
that underlies sarcopenia that is not captured by QMLT, which is purely quantitative. 
While QMLT may not be a perfect tool as a one-time assessment, its value as a serial 
measurement warrants exploration, as QMLT has shown reliability to detect changes to 
resistance training over time11, and thus perhaps the dynamics of QMLT may be more 
telling than a single absolute value. 
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Muscle quality is another factor that deserves future study. All assessments in the present 
study relied on gross muscle size estimations and clinical functional testing, but no 
assessment of muscle architecture was included.  Intramuscular adipose content, fibrosis, 
density of mitochondria, exhaustion of muscle satellite cells, and degradation of motor 
end plates could all represent significant factors that better inform a patient’s underlying 
degree of sarcopenia/frailty.8, 9 These variables are not necessarily appreciable with 
standard cross-sectional imaging, strength testing, and other available measurement tools 
in clinical practice. Correlation between histologic and biochemical parameters of 
skeletal muscle with currently available assessment tools, such as muscle density on 
cross-sectional imaging, warrants exploration in the future. 
 
It was seen in this study that cross-sectional area of all abdominal muscles at the level of 
L3 had the greatest discrimination for sarcopenia. This finding is limited to males, as 
there were insufficient females with complete data to allow for analysis. The variable 
timing in administration of CT scans also possibly confounds our results. Future studies 
should look to validate this CT metric by examining recipients’ muscle mass in a 
systematic and controlled fashion to improve the validity of this metric in this population, 
and to refine normative values.  The impact of CT measurements of muscle on clinical 
outcomes would then be considered with greater confidence. We hope to continue to 
accrue patients in an ongoing effort to augment the number of patients with CT scans 
available for assessment, however ethics board standards limits the ability to expose 
potential recipients to CT scan radiation without clinical justification which could hinder 
future numbers as it did in the present cohort. Regardless, greater numbers of CT-derived 
metrics will allow for examination of these values and the relationship to clinical 
outcomes, similar to the way QMLT was studied here. 
 
Lastly, consensus on simplifying the definition of sarcopenia in the renal failure and 
transplant population should be sought: current application of operational criteria for 
sarcopenia in this population remains theoretical.10 This would achieve improved 
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standardization of research protocols to allow confidence in comparing outcomes, and 
would provide basis to help classify patients accurately in the clinical context for risk 
stratification and intervention. 
 
The impact of frailty and sarcopenia on outcomes of renal transplant are maturing and 
gaining importance for consideration in the assessment of potential transplant recipients.  
As the prognostic impact of these metrics is further clarified, an impetus to incorporate 
formal testing into the assessment process for prospective transplant recipients arises.  
The multitude of frailty instruments and different ways to assess the components of 
sarcopenia potentially leaves clinicians and assessment programs at an impasse over 
which method would be the most feasible and informative. The QMLT was assessed as a 
potential surrogate for frailty and sarcopenia with the potential to be a single-step 
assessment that could simplify the multifaceted testing of frailty and sarcopenia. This 
report supports a potential role for the QMLT, but its validity remains to be confirmed, 
and other forms of assessment such as CT of the abdomen along with possibly expanded 
appendicular muscular assessment with ultrasound require further exploration to identify 
valid cut-offs for clinical prognostication. The goal of finding a simple, feasible and 
meaningful screening metric remains to identify those at greatest risk of complications.  
Identifying such individuals would ideally lead to improved risk counselling and 
potentially allow for invitation of these patients into therapeutic programs that may 
involve prehabilitative exercise, pharmacotherapy, or dietary interventions that could 
alter the progression of frailty and sarcopenia. 
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Appendices 
  
Appendix 1. Frailty phenotype data collection sheet and cut-off references for 
strength, walk time, activity levels, exhaustion, weight loss  
From: https://www.cgakit.com/fr-1-frailty-phenotype 
 
1 
 
FRAILTY PHENOTYPE 
 
 
NAME     _________________________________________________ 
 
d.o.b.      _________________ 
 
Date        _________________ 
 
 
Administered by  __________________________________________ 
 
 
 
 
SCORING 
 
0     =   robust 
1-2  =  pre-frail 
3-4  =  frail 
5      =  very frail 
 
 
NOTES : 
 
 
  
CRITERIA OPTIONS WEIGHT SCORE 
    
Unintentional weight loss no 0 
______  yes 1 
    
Physical Activity Not limited or little limited 0 
______  Limited a lot 1 
    
Low resistance/exhaustion 0 to 2 days  0 
______  3 to 7 days 1 
    
Strength  < 20% weaker   0 
______  > 20% weaker 1 
    
Walking Time Not slower 0 
______  Slower 1 
    
  TOTAL SCORE ______ 
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2 
 
DEFINITIONS 
 
Unintentional weight loss : 
>5% weight loss over past year  
or 
 >4,5 Kg weight loss over past year 
 
Physical Activity : 
Health imposes a limit on vigorous activities such as, mowing the lawn, raking, gardening, hiking, 
jogging, biking, exercise cycling, dancing, aerobics, bowling, golf, swimming, other sport. 
 
Low resistance/exhaustion : 
Frequency that, in the past week, the individual felt that everything s/he did was an effort 
or 
s/he could not "get going" 
 
Strength : 
Without dynamometer :  
Estimated 20% weaker than expected in an  individual of similar size (BMI) 
or 
With dynamometer ( stratified by gender and Body Mass Index quartiles ) 
 
Men Cutoff for grip strength (Kg) 
criterion for frailty 
BMI < 24                        < 29 
BMI 24.1–26 <30 
BMI 26.1–28 < 31 
BMI > 28 <32 
  
Women Cutoff for grip strength (Kg) 
criterion for frailty 
BMI < 23 < 17 
BMI 23.1–26 < 17,3 
BMI 26.1–29 < 18 
BMI > 29 <21 
 
Walking Time :  
 ( stratified by gender and height ) 
 
Men Cutoff for Time to Walk 15 feet 
criterion for frailty 
Height  >  173 cm 6 seconds 
Height  <  173 cm 7 seconds 
  
Women Cutoff for Time to Walk 15 feet 
criterion for frailty 
Height  >  159 cm 6 seconds 
Height  <  159 cm 7 seconds 
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